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1 Summary 
Scope of the sponsor’s submission  
The sponsor proposes the use of EXOGEN Express for well aligned and 
stable fractures of the long bones at delayed union (after 3 months with no 
radiological evidence of healing) rather than routine observation followed by 
further surgery if necessary at diagnosis of non-union (failure of healing after 
9 months).  It is not clear whether this meets the requirements of the scope, 
which asks for a comparison of EXOGEN with surgical treatment. However, if 
current practice would be to not offer further surgery for uncomplicated 
delayed union fractures, then the comparison presented in the submission 
might be clinically appropriate.  Clinical advice suggests that ‘prophylactic’ 
surgery for fractures of the long bones does sometimes take place between 3 
and 9 months post-fracture, but that this varies according to expectations of 
individual healing times – for example, patients with fractures of the tibia or 
with indicators of impaired healing (e.g. smoking), might not be expected to 
heal until 6 months anyway, and so would be less likely to be offered surgery 
in advance of a diagnosis of non-union.  
For non-union fractures, the submission presents a direct comparison 
between EXOGEN and surgery, and is therefore consistent with the scope. 
Summary of clinical evidence submitted by the sponsor 
Evidence for delayed union 
The Schofer RCT of EXOGEN versus placebo reported healing rates of 65% 
versus 46% over four months of follow up.  This difference was not statistically 
significant (hazard ratio 1.69, p=0.07).  No device-related adverse events 
were reported in the EXOGEN arm of this study. 
Estimates of the absolute rate of healing with EXOGEN are provided by 
registry data (Mayr 2000). For non-union, 90% of long bone fractures healed 
in a mean time of 4.4 months.  Two other delayed union case series reported 
healing rates with EXOGEN: of 83% (Jingushi 2007), time to healing not 
reported; and 94% (Lerner et al. 2004) over a mean of 17 months.  
Other outcomes requested in the scope (‘return to painless weight bearing’ 
and ‘avoidance of surgery’) were not reported.  
No estimates of healing rates following surgery in people with delayed union 
fractures of long bones were identified. 
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Evidence for non-union 
There was no direct comparative evidence of the effect on healing rates or 
other outcomes of interest for EXOGEN versus surgery in non-union fractures 
of long bones.  However, independent estimates of healing rates for the two 
interventions were available from non-comparative case series. 
The mean healing rate for non-union long bone fractures was reported in the 
Mayr analysis of EXOGEN registry data: 84% over a mean of 5.3 months. 
Other estimates ranged from 66% for a mixture of long bone fractures 
(Jinguishi et al. 2007) to 95% for radius/ulna fractures and 100% for tibia and 
tibia/fibula fractures (Mayr et al. 2000).  No device-related adverse events 
were reported in the EXOGEN studies.  Other outcomes requested in the 
scope (‘return to painless weight bearing’ and ‘avoidance of surgery’) were not 
reported, although in the context of non-union it is reasonable to suppose that 
patients whose fractures healed following use of EXOGEN would have 
otherwise required surgery. 
For non-union long bone fractures treated by surgery, healing rates ranged 
from 62% to 100%, and healing time ranged from 9 weeks (Livani et al.  2010) 
to 24 weeks (Ring et al. 1997). There were some reports of time to weight 
bearing, but these may not be consistent with the scope. Further surgery and 
adverse events due to surgery were reported in some papers.  
Summary critique of clinical evidence submitted by the sponsor  
Delayed union 
The EAC considers that the best estimate of the absolute rate of healing in 
patients with delayed union fractures treated with EXOGEN is 90% (87% to 
92%) healed in a mean time of 4.4 months (Mayr 2000). This comes from a 
large registry database, with definitions of delayed union and non-union that 
match those in the scope, and with results reported separately for different 
long-bone and non long-bone fractures.  Other estimates vary and are difficult 
to pool, due to differences in definitions and failure to report duration of follow 
up.  
However, no evidence was available to estimate a comparable rate of healing 
with surgery.  It is therefore not possible to compare EXOGEN with surgery in 
this population. 
A sham-controlled randomised trial compared EXOGEN with delay in further 
surgery for a population of patients with fractures of the tibia (Schofer 2010).  
This trial failed to detect a significant improvement in the rate of healing with 
EXOGEN (hazard ratio 1.69 (p=0.07) over 4 months), although it was not 
powered to detect differences in healing rates, and it did report statistically 
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significant improvements in indicators of progression towards healing (bone 
mineral density and bone gap area).  The applicability of these results to 
delayed union fractures is questionable, as the study included a large 
proportion of fractures which, under the definition of the scope, may be 
considered to be non-unions (failure of healing after 9 months). 
Non-union 
The EAC considers that the best estimate of the absolute rate of healing for 
non-union fractures treated with EXOGEN is 84% (80% to 89%), with a mean 
time to healing of about 5.3 months (Mayr 2000) – based on the same large 
registry database as the non-union estimate.  As with delayed union, 
estimates from other studies vary and cannot be pooled. 
Estimates of healing rates following surgery for non-union long bone fractures 
are available, but the evidence is of poor quality.  The submission included a 
review of surgical case series, reporting healing rates from 62% to 100%, and 
healing times from 9 weeks to 124 weeks.  However, the included studies 
differed in population, intervention and outcome, and it is not clear that they 
were identified systematically. The sponsor also cites Gebauer et al (2005), 
who report a mean healing rate of 86% based on 23 published studies of 
surgery in patients with non-union fractures (range 68% to 96%). But this did 
not appear to be based on a systematic review either, and it included some 
studies of non long bone fractures. 
Adverse events 
None of the EXOGEN studies included reports of any device-related adverse 
events. There are rare reports of localised pain or irritation following use of 
EXOGEN – possibly reactions to the contact gel – and isolated reports of 
possible interactions with implantable devices.  In contrast, several surgery 
studies reported adverse events, including infections. 
Summary of economic evidence submitted by the sponsor 
The sponsor reviewed published economic evidence related to the scope.  
They found one study (Taylor 2009) that estimated the net cost of alternative 
treatment strategies for patients with fresh (out of scope) and non-union 
fractures of the tibia.  This used a Markov model, with monthly cycles over a 
time horizon of one year.  The other two studies (Kanakaris 2007 and Patil 
2006) were non-comparative analyses, estimating the cost of surgical 
treatment for patients with non-union fractures of long bones. 
The sponsor also submitted two models: one for delayed union and one for 
non-union.  These models were adapted from the published model by Taylor 
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et al (2009).  The sponsor concluded that EXOGEN is a cost-saving option for 
early use in delayed union and also as an alternative to surgery in non-union. 
Summary critique of economic evidence submitted by the sponsor  
The economic models submitted by the sponsor are of a good general 
standard.  We found a few minor errors in coding and data entry.  However, in 
adapting the Taylor model, the sponsor made some adjustments to modelling 
assumptions and parameters, some of which are more questionable.  In 
particular, the method by which healing rates were extracted from the key 
clinical studies (Mayr and Schofer) and converted to monthly rates led to an 
overestimation of the likely relative effectiveness of EXOGEN compared with 
the control arm in the delayed union model.   
The non-union model relies on an assumption of equal effectiveness for 
EXOGEN and surgery, for which there is only weak evidence.  This model is 
also driven by the estimated cost of surgery itself, which is subject to 
uncertainty.  The sponsor’s estimate, based on clinical opinion, was higher 
than the relevant HRG-based reference costs. 
Both models also increased the rate of infection and the cost of infections, 
compared with the results reported in Taylor (2009).  
External Assessment Centre commentary on the robustness of evidence 
submitted by the sponsor 
The EAC corrected errors in coding and data entry, and found that they made 
little difference to the results.  However, changes to the methods for 
calculating monthly healing rates from the clinical studies for the delayed 
union model (Mayr and Schofer) meant that early use of EXOGEN in this 
context did not appear to be cost-saving – based on its preferred model, the 
EAC estimated that use of EXOGEN in delayed union costs approximately 
£500 more per patient than waiting and providing surgery at non-union if 
required. 
We found the results of the non-union model to be more robust: with an 
estimated saving with EXOGEN of approximately £1,200 per patient 
compared with immediate surgery.  EXOGEN remained cost-saving under a 
range of scenarios.  Only under a ‘worst case’ scenario of the healing rate 
with EXOGEN (82%) and the relative risk of healing with surgery (2.5), did 
EXOGEN not appear to be a cost-saving alternative to surgery for non-union. 
We also tested reductions in the rate and cost of infections, but found that 
these made little difference to the results – since the absolute number of 
patients developing an infection in any of the treatment arms is small.  
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2 Background  
2.1 Overview and critique of sponsor’s description of clinical 
context 
The sponsor sets the clinical context by explaining that there are two versions 
of the EXOGEN ultrasound bone healing system that are applicable to the 
decision problem defined in the scope: 
 EXOGEN Express, designed to treat delayed union fractures (no 
radiological evidence of healing after approximately 3 months).  This 
delivers up to 150 daily treatments (nearly five months); and 
 EXOGEN 4000+ designed for non-union fractures (failure of healing 
after 9 months), which delivers at least 191 days of treatment (over six 
months). 
The devices are single use – one per patient – and non-rechargeable.  They 
are designed to be used by the patient at home, although as noted in the 
scope, some patients might require assistance.  The sponsor argues that 
there are no additional costs for consumables, tests or investigations, 
facilities, technologies or infrastructure required for delivery of the 
intervention.  This may be reasonable, as the device appears to be simple to 
use, however there may be some opportunity costs associated with providing 
information to patients during routine appointments.  If EXOGEN is successful 
at averting the need for further surgery, as claimed in the submission, it might 
present an opportunity for the NHS to redirect resources from these services. 
The sponsor notes that the scope is limited to delayed and non-union 
fractures of the long bones: which were defined as the humerus, ulna, radius, 
femur, tibia and fibula for the purposes of this evaluation.  These fractures 
reduce patients’ quality of life and general well-being, and treatment can be 
complex and protracted, incurring high costs for the NHS.   
The incidence of long bone fractures is estimated from Health Survey for 
England 2002-4 data (Donaldson et al 2008) at approximately 1.2 per 100 
person years for men, and 0.8 per 100 for women.  Assuming that around 5-
10% of these fractures will not heal as expected (Rubin 2001), and an adult 
population of 40.2m, the sponsor estimates a potential treatment population 
25,536 - 51,072 people per year.  This estimate appears reasonable, although 
it is unclear how many patients would meet other criteria for use of the 
technology, including the size of inter-fragment gap (<10mm), and the stability 
and alignment of the fracture (Figure 1, p17).   
The sponsor’s proposed pathways of care with EXOGEN are outlined on p19-
20 and in Figure 1 of the submission.  These pathways and those for current 
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practice are further defined in the description of the cost model (p124-129) 
and Figure 7.  However, there is some ambiguity in these descriptions: for 
example, Figures 1 and 7 do not distinguish between pathways for delayed 
and non-union, or explain how the two fit together.  Our understanding of the 
current and proposed pathways outlined in the submission and consistent with 
the cost model are described below, and illustrated in Figure 1. 
A) Current pathway of care 
Patients have treatment immediately after fracture, with open or closed 
reduction, X-rays to verify alignment, immobilisation with a plaster or splint, 
and possibly insertion of internal or external fixings as appropriate.  Those 
who do not show progress to healing by three months (delayed union) would 
not usually receive further surgery at this time, unless they had particular 
indications (e.g. unstable or mis-aligned fractures, or an inter-fragment gap of 
more than 10mm).  If, however, the bone had failed to heal by nine months 
after the original injury (non-union), then further surgery would be required. 
B) EXOGEN for delayed union 
The sponsor suggests that the EXOGEN Express device should be used at 
the point of delayed union for patients with stable, well-aligned fractures, with 
a gap less than 10mm.  The patient would use the device for 20 minutes per 
day, until their fracture heals or the device expires.  Patients with non-union 
fractures following use of EXOGEN Express would have surgical treatment. 
C) EXOGEN for non- union 
The sponsor proposes use of the EXOGEN 4000+ device at the point of non-
union for patients with stable, well-aligned fractures, with a gap less than 
10mm.  The device would be used daily for 20 minutes until healing or expiry 
of the device, followed by surgery if the fracture was still unhealed at that time 
(approximately six months after the point of non-union).     
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Figure 1.  Illustration of care pathways 
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For delayed union, the effectiveness data and cost model presented in the 
submission compare EXOGEN Express with routine observation.  It is not 
clear that this meets the requirements of the scope, which asks for a 
comparison of EXOGEN with surgical treatment. However, if current practice 
would be to not offer further surgery for uncomplicated delayed union 
fractures (stable and well-aligned), then the comparison presented in the 
submission might be clinically appropriate.  Our understanding is that some 
patients would have surgery between 3 and 9 months, but that this would 
differ according to expectations of healing according to bone type and 
individual risk factors for impaired healing. 
For non-union fractures, the submission does present a direct comparison 
between EXOGEN and surgery, and is therefore consistent with the scope. 
An important aspect of the care pathway reflected in the costing model is the 
risk of post-surgical infection, particularly of ‘deep’ bone infections 
(osteomyelitis).  Reducing the risk of infection by avoiding the need for further 
surgery is an element in the sponsor’s argument that EXOGEN is clinically 
superior and cost-saving.  Estimates of the incidence of infection and the 
costs of treating infections are discussed in section 3 below. 
It should also be noted that the cost model presented relates only to the case 
of a tibia fracture initially treated by surgical insertion of an intramedullary (IM) 
nail.  The sponsor chose to focus on Tibia fractures as they are a common 
cause of healing problems, and there is sufficient data to allow modelling.  
Though cost and patient impact do differ for other long bone fractures, the 
tibia is probably a reasonable exemplar – femoral non unions are more 
disabling and difficult to treat, but upper limb fractures are less so. 
 
2.2 Overview of sponsor’s description of ongoing studies 
Ongoing studies – section 5.1 of sponsor’s submission.  The sponsor states 
that there are no ongoing studies relevant to the scope of the submission.   
We identified one ongoing study listed in the ClinicalTrials.gov register that is 
potentially of relevance – the TRUST trial, NCT00667849.  This is a 
multinational randomised placebo-treatment controlled clinical trial to evaluate 
the EXOGEN Bone Healing System for adults with tibial fractures treated with 
intramedullary nailing.  Estimated enrolment is 500 patients and outcomes 
include time to healing, followed up to 12 months.  It is sponsored by Smith 
and Nephew, and is stated to be due to complete in December 2012.  Dijkster 
et al (2011) report an analysis for 51 patients from the TRUST feasibility trial, 
assessing the effect of adding clinical notes to radiographs in adjudication of 
fracture healing. It is not explicitly stated in the clinical trial register, or in 
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Dijkster et al 2011, but it appears that the sample largely or wholly comprises 
patients with fresh fractures.  If so, this study would fall outside the scope of 
this current assessment. 
The PUSH-IT trial (ISRCTN90844675), which is registered in the Current 
Controlled Trials register as completed but has not yet reported, is a 
randomised comparison of adjuvant EXOGEN compared with a ‘standard of 
care’ control after intramedullary nailing of tibia fractures.  This study is 
sponsored by the German Employer's Liability Insurance for the 
Administrative Professions.  Again, it appears that this study relates wholly or 
largely to fresh fractures, and so is out of scope. 
We therefore agree with the sponsor’s conclusion that there are no ongoing 
studies relevant to the scope of this evaluation. 
 
2.3 Critique of sponsor’s definition of the decision problem 
Population 
The scope defines the population as: “patients with long bone fractures with 
non-union (failure of healing after 9 months) or delayed healing (no 
radiological evidence of healing after approximately 3 months).” 
The sponsor specifies that the long bones to include in this evaluation are: 
humerus, ulna, radius, femur, tibia and fibula (Glossary p10).   
In their summary of included papers (Table B3, page 34), the sponsor lists 9 
clinical studies of EXOGEN and 10 of surgery, although they later excluded 
one of the EXOGEN studies (Pigozzi 2004) as only 2 out of 15 patients had a 
fracture of a long bone.  The population characteristics for the remaining 18 
studies are summarised in Table 1 below. 
The studies were conducted in 12 countries, but none in the UK.  This might 
potentially limit applicability of the findings to patients treated in an NHS 
context.  For example, differing practice in treating the initial fracture might 
possibly influence clinical features of delayed union and non-union fractures, 
making them more or less amenable to ultrasound treatment. 
The mean age of study participants was around 30-50 years, but there was a 
wide range (13 to 92).   
The EXOGEN studies included patients with fractures classified as delayed 
union (3 studies), non-union (4 studies) and both (2 studies).  However, 
definitions of delayed union (DU) and non-union (NU) varied between studies, 
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and often differed from the definitions in the scope.  For example, Schofer et 
al defined delayed union as a “lack of clinical and radiologic evidence of 
union, bony continuity or bone reaction at the fracture site for no less than 16 
weeks from the index injury or the most recent intervention” (Schofer 2010).  
But 51 of the 101 patients in this trial had fractures that had not healed for 
over 9 months at study entry, and would therefore appear to fit the scope 
definition of non-union.  No subgroup analysis comparing results for delayed 
union and non-union fractures was presented.  The Schofer trial is an 
important study, as it is the only sizeable randomised controlled trial of 
EXOGEN, and it is a key input to the costing model for delayed union.  
However, its applicability to this context is unclear, because under the 
definition of the scope it included a large proportion of patients with non-union 
fractures (failure of healing after 9 months).       
The other main source of effectiveness evidence used in the costing model 
comes from a registry of patients treated with EXOGEN, reported in Gebauer 
(2005) and Mayr (2000).  The EXOGEN registry uses definitions of delayed 
and non-union, which are consistent with those in the scope.   
The surgery case series - included for comparison with the largely 
uncontrolled EXOGEN studies – all related primarily to non-union fractures, 
although a few included patients with unhealed fractures of less than 9 
months duration. 
The studies included a mix of different long bone fractures, and some 
included other bones as well (where possible these data have been excluded 
from the summary of study outcomes).  However, the only randomised 
evidence relevant to the scope relates to the tibia (Schofer 2010): although 
(Rutten 2008) report a small RCT of fibula, this did not include any outcomes 
specified in the scope.  There is no direct evidence of the effectiveness of 
EXOGEN compared with surgery in patients with delayed union or non-union 
fractures of other long bones.  For this reason, the costing model is restricted 
to tibia fractures.  It may be questioned how generalisable the clinical 
evidence and cost estimates are to long bones other than the tibia, although 
this might be a reasonable exemplar.   
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Table 1.  Summary of patient populations for included clinical studies 
Study Country Long bone  Delayed
/ non-
union 
Mean 
fracture age 
(months) 
Mean 
patient age 
(years) 
EXOGEN STUDIES 
Schofer 2010 * Germany Tibia DU/NU? 
13  
51/101>9m 
43 (14-70) 
 
Rutten 2008 Netherlands Fibula DU 
6-11 
2/13>9m 
42-63 
Lerner 2004 Israel 
Femur, tibia, 
radius/ulna, 
humerus 
DU 6 (1-38) 19-48 
Jingushi 2007 Japan 
Femur, tibia, 
humerus, 
radius, ulna 
DU/NU 19 (3-159) 40 (14-83) 
Mayr 2000 * Germany 
Femur, tibia, 
fibula, radius, 
ulna, humerus 
DU/NU 
951 3-9m 
366 >9m 
20 - 71 
Gebauer 2005 * 
Germany & 
Austria 
Tibia, fibula, 
femur, humerus, 
radius, ulna 
NU >8 23-86 
Nolte 2001 Netherlands 
Humerus, 
radius, ulna, 
femur, tibia, 
fibula 
NU 
15 (6-34) 
5/21<9m 
18-90 
Romano 1999 Italy 
Tibia, humerus, 
femur 
NU 
(septic) 
8-30 
1/13<9 
28-78 
SURGERY STUDIES 
Bellabarba 2002 USA Femur NU 10 (3-25) 48 (18-92) 
Birjandinejad 2009 Iran Femur, tibia NU - 31 (18-52) 
Cacchio 2009 Italy 
Femur, tibia, 
ulna, radius 
NU 11 43  
Friedlaender 2001 USA Tibia NU 33 34 
Khalil 2010 Egypt Ulna NU  42 
Lin 2010 Taiwan Humerus NU >6m 
42 
55 
Livani 2010 Brazil Humerus NU >8m 38 (18-74) 
Razaq 2010 Pakistan Femur NU - 40 
Ring 1997 USA Femur NU 17 (6-68) 35 (13-81) 
Wu 2003 Taiwan Tibia NU 22 (10-48) 34 (19-58) 
* Clinical evidence used in costing model 
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Intervention 
The technology described in section 2 of the submission (p14) relates to the 
EXOGEN ultrasound bone healing system, as specified in the scope. Two 
versions of the device are available; the EXOGEN Express designed for 
delayed union fractures, and limited to 150 20 minute treatments; and the 
EXOGEN 4000+ designed for non-union fractures, which delivers a minimum 
of 191 20 minute treatments. 
The sponsor submitted certification of approval by: the Medical Devices 
Bureau of Canada; the Australian Department of Health and Ageing 
Therapeutic Goods Administration; the British Standards Institution; the US 
Food and Drug Administration; EC Medical Devices Directive CE marking; 
BSI Management Systems Japan.   
The intervention studies reported in the submission, and those informing the 
cost analysis, all relate to versions of the EXOGEN device (sometimes under 
the name of SAFHS). 
Comparator(s) 
The comparators specified in the scope were surgical treatment, including 
internal and external fixation, with or without bone grafting.  The interventions 
and comparators for studies included in the submission are summarised in 
Table 2 below. 
The submission did not identify any studies directly comparing EXOGEN with 
surgery for people with delayed or non-union fractures of the long bones.  
The Schofer trial compared the use of EXOGEN with a sham device (Schofer 
2010).  Most of the participants in this study had previously received surgery 
(including intramedullary (IM) nailing, locking screws, external fixation, 
osteosynthesis place and supplemental bone graph), but patients who had 
revision surgery or reoperations at the fracture site within four months were 
excluded.  Schofer et al, does not, therefore, provide direct evidence for the 
requested comparison of EXOGEN vs. surgery.   
So, as noted above, the sponsor’s cost model does not compare EXOGEN 
with immediate surgery at the point of delayed union.  Instead it is assumed 
that both groups would have received surgical intervention shortly after the 
time of injury, and EXOGEN is compared with routine observation at the point 
of delayed union followed by further surgery for both groups at the point of 
non-union if required. 
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Table 2.  Summary of study design, interventions and comparators for included clinical studies 
Study Delayed/ 
non-union 
Study 
design 
Intervention Comparator 
EXOGEN STUDIES 
Schofer 2010  DU/NU? RCT EXOGEN Sham device 
Rutten 2008 DU RCT EXOGEN Sham device 
Lerner 2004 DU Case series 
EXOGEN  
 
 
Jingushi 2007 DU/NU Case series EXOGEN  
Mayr 2000  DU/NU Case series EXOGEN  
Gebauer 2005  NU Case series EXOGEN  
Nolte 2001 NU Case series EXOGEN  
Romano 1999 NU Case series EXOGEN  
SURGERY STUDIES 
Bellabarba 2002 NU Case series Plate & screws  
Birjandinejad 2009 NU Case series 
Plate & screws 
after IM nailing 
 
Cacchio 2009 NU RCT Surgery Shock Wave* * 
Friedlaender 2001 NU RCT 
Surgery  
+ rhOP-7 
Surgery + 
autograft 
Khalil 2010 NU Case series Contour plate  
Lin 2010 NU 
Prospective 
comparison 
Surgery 
+ allograft 
Surgery 
+ autograft 
Livani 2010 NU Case series Plating  
Razaq 2010 NU Case series 
Exchange  
nailing 
 
Ring 1997 NU Case series Wave plate  
Wu 2003 NU Case series 
Reaming  
bone grafting 
 
* Outside scope 
For non-union, the sponsor argues that case series of patients treated with 
EXOGEN alone can provide sufficient evidence of effectiveness – since one 
would not expect any healing in these patients in the absence of treatment.  
Therefore, non-union patients may provide their own control – the studies are 
referred to as ‘self-paired’ (Gebauer 2005, Jingushi 2007, Nolte 2004 and 
Romano 1999).   
However, this self-paired data does not provide evidence of the relative 
effectiveness of surgery and EXOGEN in non-union.  The sponsor therefore 
had to rely on estimates of the absolute healing rate from separate case 
series of surgery and EXOGEN.  This approach is vulnerable to bias due to 
differences between the study populations and contexts.   
The sponsor’s cost model for non-union bases the estimated healing rate with 
EXOGEN on registry data reported in Mayr (2000), and assumes equal 
effectiveness for surgery in this population.  The latter assumption is based on 
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a comparison of a subset of local registry data presented by Gebauer et al 
(2005) and the pooled result of a review of published case series of non-union 
surgery presented in the same paper.  However, this review did not appear to 
be systematic (no search strategy was presented), and it included studies of 
non long-bone as well as long-bone fractures.  The sponsor also presented 
their own review of the non-union surgery case series literature.  This did use 
a systematic strategy to identify and select studies (section 7.1 and 7.2, p27-
32), but it is not clear that all relevant studies were retrieved: “EXOGEN data 
was identified first and then surgical data was matched as closely as possible 
to the methodologies and design of the relevant papers” (p28).  The 
assumption of equal effectiveness for surgery and EXOGEN in non-union 
fractures is based on weak non-comparative evidence.  If surgery were to be 
more effective than EXOGEN at this point in the pathway, then the sponsor’s 
conclusion that EXOGEN is dominant for non-union fractures might not be 
justified.  We therefore tested changes to the relative risk of healing with 
surgery compared with EXOGEN in our sensitivity analysis. 
 
Outcomes  
Outcomes requested in the scope are: 
 Bridging on radiograph (3 out of 4 cortices bridged); 
 Fracture healing time; 
 Return to painless weight bearing; 
 Avoidance of further surgery; and  
 device-related adverse events. 
The availability of these outcomes is reported in Table 3.  Most studies 
reported healing rates and healing times, however reporting of the other 
outcomes was sparse.  The sponsor mentions the lack of accepted methods 
for diagnosing delayed and non-union fractures, including differing time 
thresholds and clinical and radiographic criteria (section 3.4 p18).  This 
complicates the assessment of outcomes in the clinical studies. 
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Table 3.  Summary of reported outcomes for included clinical studies 
Study Bridging on 
radiograph 
Healing 
rate 
Healing 
time 
Painless 
weight bearing 
Further 
surgery 
Adverse 
events 
EXOGEN STUDIES 
Schofer 2010  No
3
 Yes No No No
2
 Yes 
Rutten 2008 No
3
 No No No No No 
Lerner 2004 No
3
 Yes Yes No No No 
Jingushi 2007 Yes Yes
1
 No No
1
 No
2
 No 
Mayr 2000  No
3
 Yes Yes No No
2
 No 
Gebauer 2005  No
3
 Yes
1
 Yes No
1
 No
2
 No 
Nolte 2001 No
3
 Yes Yes No No
2
 No 
Romano 1999 No
3
 Yes Yes No Yes No 
SURGERY STUDIES 
Bellabarba 2002 No
3
 Yes Yes No Yes Yes 
Birjandinejad 2009 No
3
 Yes Yes No Yes Yes 
Cacchio 2009 Yes Yes No No No Yes 
Friedlaender 2001 Yes Yes No Yes Yes Yes 
Khalil 2010 Yes Yes Yes No Yes Yes 
Lin 2010 No
3
 Yes Yes No Yes No 
Livani 2010 Yes Yes Yes No No Yes 
Razaq 2010 No
3
 Yes Yes No No Yes 
Ring 1997 No
3
 Yes Yes Yes Yes Yes 
Wu 2003 No
3
 Yes Yes No No Yes 
1 Definition of ‘healing’ in these studies included painless weight bearing, although time to painless 
weight bearing was not reported. 
2 Non-union fractures that healed with EXOGEN are unlikely to have healed if EXOGEN had not been 
used.  Healing rates for non-union fractures reported in these studies are therefore suggestive of 
avoidance of further surgery. 
3 Not reported separately from other criteria of healing. 
 
Cost analysis 
The sponsor’s cost models deviated from that requested in the scope in 
several ways.   
 Comparison between EXOGEN and surgery 
The non-union model compared immediate surgery with EXOGEN, 
followed by further surgery for both groups after six months if needed.  
This reflects the comparison requested in the scope.  However, the 
delayed union model compared use of EXOGEN at 3 months with no 
further intervention at this time, followed by surgery at nine months if 
required.  This does not directly address the comparison asked for in 
the scope, although it might be a relevant comparison if current clinical 
practice is to not offer further surgery until 9 months post-fracture. 
 NHS and PSS Perspective 
The cost models only included NHS costs.  It is argued that this is a 
conservative approach, and that inclusion of personal social service 
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costs would only increase the estimated cost savings with EXOGEN.  
This is a fair point. 
 Time horizon sufficiently long to reflect differences  
The cost models only followed patients for a 12-month time horizon, 
which will not capture all differences in costs and health consequences.   
In the delayed union model, the sponsor assumes that a greater 
proportion of fractures will be healed by 12 months when patients are 
treated with EXOGEN.  This implies that a greater proportion of costs 
will be omitted for the non-EXOGEN arm, so the short time horizon will 
tend to bias results against EXOGEN. 
However, for the non-union model, the impact of the short time horizon 
is much more uncertain.  Although the sponsor assumes equal rates of 
healing with EXOGEN and surgery, they also assume a higher infection 
rate with surgery, which leaves a greater proportion of the cohort 
unhealed after 12 months in the surgery arm.  As argued above, this 
would tend to bias the cost estimates against EXOGEN.  But evidence 
supporting the assumption of equal effectiveness is poor.  In sensitivity 
analyses where surgery is assumed to give a better healing rate, the 
bias from the short time horizon would be favouring EXOGEN. 
 Sensitivity analyses 
The model does not include probabilistic sensitivity analysis, which 
would have been helpful in understanding the overall extent and impact 
of uncertainty over model parameters.  The deterministic sensitivity 
analysis presented in the submission is also very limited.  The only 
parameters that were varied were the healing rate with EXOGEN and 
the comparator, and the monthly rate of infection (which was only 
increased, not decreased).  We argue below that there are other 
important sources of uncertainty, and extend the sensitivity analysis of 
the cost models. 
 Scenario analysis for risk sharing scheme 
Not presented.  The EAC does not have sufficient information to 
estimate the impact of this scheme ourselves. 
Subgroups 
The results of the clinical studies are summarised separately for non-union 
and delayed healing fractures, as requested in the scope.  However, results 
are not presented for different long bone fractures, and the cost model only 
estimates results for tibia fractures. 
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It is noted in section 9.6.1, that the Taylor (2009) economic evaluation, on 
which the sponsor’s cost model is very largely based, reported a subgroup 
analysis for patients with fresh fractures at high risk of delayed healing and 
increased infection rates – exemplified by smokers.   
Special considerations, including issues related to equality 
The scope notes that because treatment with EXOGEN is self-administered, 
some patients might need assistance in using the technology. 
The submission does not identify any further equalities issues. 
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3 Clinical evidence 
3.1 Critique of the sponsor’s search strategy 
Identification of studies 
The sponsor points to the variability in diagnosis and treatment of non-union 
fractures and problems with the quality of study design which raises difficulty 
in searching. Their stated intention is to minimise the possibility of bias and 
allow a fair comparison between EXOGEN and surgical intervention. 
Under the heading “Literature Search Strategy” the sponsor describes their 
approach to searching. Of the suggested databases (section 10.1 Appendix) 
the sponsor chose to search only one (MEDLINE via PubMed) which risks 
them increasing rather than minimising the possibility of bias. A more 
comprehensive search would have been achieved by including MEDLINE In-
Process, EMBASE and the Cochrane Library. The EAC tested this by 
recreating the sponsors search strategies as closely as possible on EMBASE 
and CENTRAL. 
The sponsor states that they also searched CRD databases but the meta-
analyses they found were not within scope.  Ideally, sources for searching for 
reviews and meta-analyses would include HTAi Vortal, TRIP database and 
general internet searches which would have located appraisals by health 
insurers, of which there are a number on this topic.  
The searches were conducted on 12th April 2012 and were divided into two 
strands – search 1 looking at the technology and search 2 looking at surgery 
for delayed/non-union fractures of long bones. The EAC replicated the 
sponsor’s searches (detailed in section 10.1) as closely as possible, resulting 
in similar yields to those obtained by the sponsor. The searches appeared to 
have pinpointed the topic areas required and to be broad enough to retrieve 
most relevant studies. There is some duplication of terms in the EXOGEN 
strategy but this would not affect the outcome. 
The surgery search has not included the term delayed union so may have 
missed some references. Because of the volume of literature yielded by this 
search when using [ALL FIELDS], a decision has been made to restrict the 
search to title only. This pragmatic decision makes sense although again risks 
missing some references.  Given the non-comparative nature of the evidence 
on surgery for non-union, this might potentially bias the results. 
The searches were limited to the years 1992-2012, presumably relating to the 
years the technology has been in use. There was also a limit to English 
language publications only, which introduces a risk of bias, particularly since 
the technology is widely used internationally. When running searches on 
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EMBASE and CENTRAL the EAC did not use a language limit to avoid this 
risk. 
The sponsor states that “identified literature from PubMed searches was used 
to source additional clinical literature and background literature”......but do not 
clarify how this was done. The EAC assumes this may have been by 
reference list searching or using the “related articles” feature in PubMed. 
The sponsor also states that “due to the large number of publications 
identified using the PubMed search terms, additional selection criteria were 
identified and used to screen articles.” The process is illustrated in the two 
flow diagrams (figs 2 and 3) under “Records screened”. Although not stated 
clearly, it seems that Tables B1 and B2 list the criteria used in the screening 
process for published and unpublished studies respectively. 
The sponsor used reference searching as a means of supplementing the 
searches. The EAC agrees this is a reliable way of locating additional relevant 
papers. 
The sponsor states that “EXOGEN data was identified first and then surgical 
data was matched as closely as possible to the methodologies and design of 
the relevant papers”. It is not quite clear what is meant by this –that the study 
designs used in the EXOGEN studies were then searched for in the papers 
identified by the surgical searches.   
In conclusion, although the sponsor did not always follow recommended 
practice in searching for clinical evidence, we obtained a similar yield on 
repeating and extending their search strategy.  However, we do consider that 
there is a potentially serious risk of bias from the use of post-hoc adjustment 
of the search strategy for the surgery studies.   
Unpublished studies 
No unpublished studies were identified.  Sources listed are internal post-
market vigilance and the annual report compiled for the FDA, together with a 
Google search. These searches could have been more extensive (pipeline 
sources, conference and annual meeting abstracts and trials registers) 
although admittedly the sponsor is likely to be aware of any unpublished 
studies relating to their own technology. 
NB It would have been helpful if the list of references at the end of the 
submission had included titles. 
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3.2 Critique of the sponsor’s study selection 
Most inclusion criteria used for the selection of studies in the sponsor’s 
submission Table B1 are consistent with the decision problem, and therefore 
are considered by the EAC to be appropriate. Patients included were adults 
with non-union or delayed unions in long bones. Studies included were 
published studies based on data collections after 1992.  The included 
outcomes were healing rate and healing time but some other outcome 
measures (e.g. return to painless weight bearing, avoidance of further 
surgery, and device-related adverse events) specified in the scoping 
document were not featured in the sponsor’s inclusion criteria.  
The exclusion criteria used for the selection of studies were reasonable. It 
excluded fresh fractures or fracture healing complications in children. As 
EXOGEN is not suitable for skeletally-immature patients, the EAC thinks it is 
sensible to exclude children from the study population. Interventions not in the 
scope or lacking healing data were also excluded. Studies having fewer than 
12 patients were excluded (and meanwhile studies having 12 or more patients 
in each series were included). This is rather a low cut-off, and the EAC noted 
that the smallest sample size of submitted studies was 13 (Rutten et al. 2008) 
and another study (Pigozzi et al. 2004) with only 2 long bone fracture patients 
was excluded. Studies in any language other than English were also 
excluded. The EAC thinks this is sensible decision and the submission did 
include studies undertaken in non-English speaking countries. Retrospective 
study design was excluded but it was not clear why the sponsor excluded this 
type of studies.  
The same inclusion and exclusion criteria were applied to identify both 
published and unpublished studies. The sponsor included a total of 18 
published studies in their submission, and no unpublished studies. 
3.3 Included and excluded studies 
Nineteen clinical studies were identified as relevant in the sponsor’s 
submission: 9 studies of EXOGEN (delayed union and non-union patients) 
and 10 of surgery (non-union patients only). These studies are presented in 
Table 4 below (adapted from Table B3 of the sponsor’s submission).  
Despite listing it in Table B3, the sponsor excluded one study (Pigozzi 2004) 
as only 2 of the 15 patients had a long bone fracture.  Therefore there were 
18 studies included in the final submission. 
The sponsor noted that they found no direct comparisons of EXOGEN and 
surgery. Therefore, they conducted separate searches for EXOGEN and 
surgical interventions in a way that the EXOGEN data was identified first and 
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then surgical data was matched as closely as possible to the methodologies 
and designs of the relevant papers. As noted above, it is unclear what this 
means, and we suggest that all studies that met the inclusion criteria should 
have been included, and that the match was not necessary.  
There were 4 RCTs, including: two comparing EXOGEN with placebo (sham 
device) in delayed union of long bone fractures; one comparing surgery with 
shockwave in long bone non-union fractures; and one comparing two different 
types of graft in surgery for non-union patients. Another study (Lin 2010) was 
a non-randomised comparative study between surgery plus allograft or 
surgery plus autograft.  The comparisons in the surgical studies are not 
relevant to the decision problem defined in the scope.  We therefore treat 
these as case series for the purpose of this evaluation.  
The remaining 13 studies are case series. The sponsor noted that four of 
these studies for non-union fractures (Gebauer 2005, Jingushi 2007, Nolte 
2001 and Romano 1999) are ‘self-paired’ studies, where the comparator was 
the non-union patients themselves, based on the assumption of no or minimal 
(5%) healing rate with no treatment.  
Table 4.  List of relevant published studies in sponsor’s submission (Table B3 p34) 
Primary study 
reference 
Population Intervention Comparator 
 
EXOGEN STUDIES 
Schofer 2010 DU/NU? EXOGEN placebo 
Mayr  2000 DU/ NU EXOGEN - 
Gebauer 2005 DU/NU EXOGEN - 
Jingushi  2007 NU EXOGEN - 
Lerner 2004 DU EXOGEN - 
Nolte  2001 NU EXOGEN - 
Romano  1999 NU (septic) EXOGEN - 
Rutten 2008** DU EXOGEN placebo 
Pigozzi  2004 * NU EXOGEN - 
SURGERY STUDIES 
Bellabarba 2002 NU Plate & screws - 
Birjandinejad  2009 NU 
Plate & screws after 
 IM nailing 
- 
Cacchio  2009 NU Surgery Shockwave 
Friedlaender 2001 NU rhBMP-7 Autograft 
Khalil  2010 NU Contour plate - 
Lin  2010 NU Surgery plus Allograft  - 
Livani  2010 NU plating - 
Razaq  2010 NU Exchange nailing - 
Ring  1997 NU Wave plate - 
Wu  2003 NU Reaming bone grafting - 
* Listed, but excluded by the sponsor – not long bone. 
** Excluded by the EAC - outcomes outside scope. 
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We did not identify any relevant studies that had been excluded from the 
sponsor’s submitted clinical evidence   
The EAC excluded one study from the sponsor’s submission (Rutten 2008), 
because it did not report outcome measures defined in the scope, but only 
indicators of progression to healing (bone mineral density, osteoid thickness). 
3.4 Overview of methodologies of all included studies 
The sponsor’s submission included summaries of the methods used for each 
of the included studies.  We have reviewed these summaries (Appendix A: 
Clinical study methods). An overview of the EAC critique of the included 
studies is provided below for delayed union (Table 5) and for non-union 
studies (Table 6). Key findings are summarised below: 
Evidence for delayed union 
 All four included studies of delayed union involved use of EXOGEN.  
One of these studies was a randomised trial comparing EXOGEN with 
placebo (Schofer 2010).  The largest of the case series, analyses data 
from a registry of patients treated with EXOGEN (Mayr 2000).   
 Although many of the participants in the included delayed union studies 
would have received surgical intervention shortly after injury, surgery 
was not used at the time of delayed union. Therefore, we cannot 
estimate the effectiveness of surgery for delayed union on the basis of 
this evidence. 
Evidence for non-union 
 Estimates of healing rates with EXOGEN and with a variety of surgical 
interventions are available from 15 case series (Table 6). The largest of 
these studies is the report by Mayr (2000), summarising healing rates 
and times from the EXOGEN registry.  
 The sponsor argues that, since no or minimal healing of non-union 
fractures is expected without further intervention, evidence of healing 
from case series is reasonably robust – patients effectively provide 
their own ‘control (the studies are ‘self-paired’).  However, independent 
case series cannot provide direct evidence for the effectiveness of 
EXOGEN compared with surgery.   
 Indirect comparison of absolute healing rates from separate case 
series is potentially biased, due to differences between study 
populations and contexts. 
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Heterogeneity between studies 
 Definitions of delayed union or non-union varied between studies. 
Some of these definitions may not be consistent with the scope. For 
example, Schofer (2010) defined delayed union as ‘lack of clinical and 
radiological evidence … for no less than 16 weeks’, Jingushi (2007) 
mentioned ‘ union…not being observed more than 3 months’, Lerner 
(2004) used ‘no radiographic evidence of fracture callus was noted 
median 6 months (ranged 4 – 38 months)’. 
 The patient population varied between studies in terms of age, fracture 
age, fracture types and smoking status.   
 Studies were conducted in 12 countries, and did not include the UK. 
This evidence might not be transferable to an NHS context if patient 
characteristics, clinical practice, or other context differs in other 
healthcare systems. 
 The position of long bone fractures varied between studies. The most 
commonly examined were tibia and femur.  
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Table 5.  Summary of methods for delayed union studies 
Study   Patient population  Country Age, fracture age Long bone type  Study design Sample size 
EXOGEN STUDIES 
Schofer 
2010* 
Lack of clinical and 
radiologic evidence of union, 
bony continuity or bone 
reaction at the fracture site 
for no less than 16 weeks 
from the index injury or the 
most recent intervention.  
Germany For EXOGEN group: 
mean age 42.6, SD 14.6 
Mean fracture age 60.3, 
SD 61.0 weeks. 
Tibia shaft RCT (EXOGEN 
vs. placebo) 
 51 EXOGEN 
vs. 50 placebo 
Mayr  
2000 * 
SAFHS worldwide 
prescription registry of 
delayed union patients (3 - 9 
months post-fracture); 
Similar patients from local 
clinic.  
Germany Fracture age ranged from 
146 - 163days. 
Humerus, Radius-
ulna, femur, 
tibia/tibia-fibula 
Prospective 
case series 
(registry) 
654 EXOGEN 
from registry;  
(42 from local 
clinic ) 
Jingushi  
2007 * 
Union or radiogical bone 
reaction not being observed 
more than 3 months after the 
most recent operation 
Japan Mean age 40.4.  
Mean fracture age 18.9 
month (3-159) 
Femur, tibia, 
humerus, radius, 
and ulna 
Case series 40 EXOGEN 
Lerner 
2004 
Patients with severe 
compound high-energy limb 
injuries and varying 
degreess of bone 
comminution and soft-tissue 
loss. No radiographic 
evidence of racture callus 
appearance was noted 4 - 38 
(median 6) months after 
prolonged fixation time.  
Israel Age ranged from 19 - 48 
yrs. 
Femur, tibia, 
radius/ulna, 
humerus 
Case series 16 EXOGEN 
* Studies involved both delayed union and non-union  
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Table 6.  Summary of methods for non-union studies 
Study  Patient population Country Age, fracture 
age 
Long bone 
type  
Study 
design 
Sample size 
EXOGEN STUDIES 
Mayr  2000 SAFHS worldwide prescription registry of 
non-union patients (the failure of a healing 
process  9 months post-fracture).  
Germany  Fracture age 
ranged from 435 - 
871 days. 
Humerus, 
radius/radiu
s-ulna, 
femur, 
tibia/tibia-
fibula 
Prospective 
case series 
(registry) 
256 
EXOGEN 
Gebauer 2005 Established non-union (minimum fracture 
age 8 months), radiographic indicated the 
healing process had stopped for at least 3 
months; a minimum of 4 months without 
surgical intervention before EXOGEN.  
Germany 
and Austria  
Age ranged 23 - 
86 yrs. 
Tibia, 
femur, ulna, 
fibula, 
humerus 
Case series 
(self-paired)  
51 EXOGEN 
Jingushi  2007 Non union defined as additional operative 
treatment being indicated for the case 
(different from the scope) .  
Japan Mean age 40.4. 
Mean fracture 
age 18.9 month 
(3-159) 
Femur, 
tibia, 
humerus, 
radius, and 
ulna 
Case series   32 EXOGEN 
Nolte  2001 Patients had a failure of the fracture to unite 
at a minimum of 6 months from fracture, 
radiographic healing had not progressed or 
had stopped for a minimum period for 3 
months before EXOGEN. The interval 
between the last operative procedure and 
EXOGEN was 3 months minimum.  
Netherlands Average age 47 
yrs (range 18 - 
90). Average  
fracture age 61 
weeks (range 25 
- 137 weeks). 
Humerus, 
radius, ulna, 
femur, 
tibia/fibula 
Case series 
(self-paired), 
assuming 5% 
healing rate 
for non-union 
without any 
interventions 
22 EXOGEN 
Romano 1999 Patients with septic non-unions: sufficiently 
stable; infection controlled with antibiotics; 
sufficient vascularisation; and skin covering 
Italy 28-78 years Tibia, 
humerus, 
femur 
Case series 15 fractures 
(13 long 
bones) 
   28 of 151 
External Assessment Centre report: EXOGEN 
Date: 22
nd
 June 2012 
Study  Patient population Country Age, fracture 
age 
Long bone 
type  
Study 
design 
Sample size 
SURGERY STUDIES 
Bellabarba 
2002 
Consecutive patients with non-union o the 
distal femur. Non-union was defined as 
failure of frature union at 6 month of the 
absence of pregrossive healing on 3 
consecutive monthly radiographs.  
USA Mean age 48 yrs 
(ranged 18 - 92). 
Interval from 
injury  to non-
union 10 months 
(ranged 3 - 25) 
distal femur Prospective 
consecutive 
study  
20 surgery 
(plate and 
screws) 
Birjandinejad  
2009 
Non-union patients after IM nailing of 
femoral and tibial fracture. Infected non-
unions were excluded. No definition for non-
union.  
Iran Mean age 31.4 
yrs (ranged 18 - 
53). 
femur and 
tibia 
case series 38 surgery 
(plate and 
screws 
augmentation 
following IM 
nailing) 
Cacchio  2009 Long bone non-union and skeletal maturity 
patients. Non-union was defined as a 
fracture that did not show any progress  
toward healing on radiographs made at 1 
month intervals for at least 6 months 
following treatment.  
Italy Mean age 42.8 
yrs (SD 6.3), 
duration of non-
union 11.5 (SD 
4.9).  
 
Femur, 
tibia, ulna, 
radius 
RCT  42 surgery  
(vs. 84 
shockwave) 
Friedlaender 
2001 
Tibial non-union patients where non-union 
was defined as 9 months duration of the 
non-united fracture with no evidence of 
progressive healing over the previous 3 
months. Patients judged for internal fixation 
along and patients with infection were 
excluded.  
USA Mean age 34 yrs 
(SD 11), 57% 
smoking, median 
non-union 
duration 33 
months. 
tibia RCT - 
partially 
blinded  
124 surgery 
(61 autograft 
vs. 63 
authograft)  
Khalil  2010 Ununited proximal ulna fracture.  Egypt Mean age 41.7 
yrs. 
ulna case series 21 surgery 
(contour 
plate)  
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Study  Patient population Country Age, fracture 
age 
Long bone 
type  
Study 
design 
Sample size 
Lin  2010 Patients with humeral shaft non-union of 
greatter than 6 months duration.  
Taiwan Mean age 42.2 
yrs (SD 18.4 for 
autograft group), 
55.3 (SD 23.5 for 
allograft group) 
humerus prospective, 
comparative 
cohort study 
65 surgery 
(plus 
allograft/ 
autograft) 
Livani  2010 Patients with humeral shaft fracture who 
had no clinical, radiological or bone scan 
signs of healing after 8 months.  
Brazil Mean age 37.53 
yrs (range 18 - 
74). 
Humerus  Case series 15 surgery 
(anterior 
plating) 
Razaq  2010 Consecutive patients of non-union fractures 
shaft of femur and had less than 1cm 
shortening with no segmental bone defect, 
and a radio lucent line of the non-union, and 
had been previously treated by IM nail.  
Pakistan Mean age 38.8 
yrs (SD 13.8) 
Femur case series 43 surgery 
(exchange 
IM nailing)  
Ring  1997 Consecutive complex un-united fractures of 
the femoral shaft patients.  
USA Mean age 35 yrs 
(13 - 81), mean 
duration of non-
union before the 
surgery was 17 
months (6 - 68).   
Femur   case series  42 surgery 
(wave-plate 
combined 
with bone 
grafting) 
Wu  2003 Patients sustained tibial shaft aseptic non-
unions after plating. 2) 
Taiwan Median age 34 
(19-58). Median 
of time from injury 
to current 
treatment was 1.8 
yrs (0.8 - 4. 
tibia case series 31surgery  
(reaming 
and IM nai)  
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3.5 Overview and critique of the sponsor’s critical appraisal 
The sponsor critically appraised each included study.  The EAC reviewed the 
sponsor’s critical appraisals, and comments for each study are provided in 
Appendix B. 
3.6 Results  
The submission included a summary of outcomes for each of the included 
studies, which we critiqued (see Appendix C).  Our summary of the results of 
the clinical studies is provided in Table 7 for delayed union and Table 8 for non-
union.  Key findings are summarised below: 
Evidence for delayed union 
 The Schofer RCT of EXOGEN versus placebo reported healing rates of 
65% versus 46% over four months of follow up.  This difference was 
not statistically significant (hazard ratio 1.69, p=0.07).   
 The analysis of EXOGEN registry data for delayed union (Mayr 2000), 
found that 90% of long bone fractures healed in a mean 4.4 months.  
 The other two delayed union studies reported healing rates with 
EXOGEN of 83% (Jingushi 2007), time to healing not reported; and 
94% (Lerner et al. 2004) over a mean of 17 months.  
 Other outcomes requested in the scope were not reported.  
Evidence for non-union 
 The mean healing rate for non-union long bone fractures reported in 
the Mayr analysis of EXOGEN registry data was 84% over a mean of 
5.3 months. Other estimates ranged from 66% for a mixture of long 
bone fractures (Jinguishi et al. 2007) to 95% for radius/ulna fractures 
and 100% for tibia and tibia/fibula fractures (Mayr et al. 2000).  There 
were no reports for other outcomes requested in the scope.  
 For non-union long bone fractures treated by surgery, healing rates 
ranged from 62% to 100%, and healing time ranged from 9 weeks 
(Livani et al.  2010) to 24 weeks (Ring et al. 1997). There were some 
reports of time to weight bearing, but these are not consistent with the 
scope. Further surgery and adverse events due to surgery were 
reported in some papers.  
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Table 7.  Summary of outcomes of delayed union studies 
Study  Healing rate Healing time Return to painless 
weight bearing 
Avoidance of further 
surgry  
Device related 
adverse events 
EXOGEN STUDIES 
Schofer 2010 65% (33/51) for EXOGEN, 46% 
(23/50) for placebo.  
Hazard ratio:1.69 (p=0.07) 
Over 16 weeks. 
Not reported not reported not reported not reported 
Mayr  2000 76% (Humerus 41/54), 
 94%(Radius-ulna 49/52), 
81% (Ulna 35/43),  
87%(femur (85/98),  
92%(tibia 350/380), 
96% (fibula, 26/27) 
 
Total 90% (586/654) 
125 days( humerus, SD 11.7), 
115 (Radius-ulna, SD 9.3),  
130 (Ulna, SD 15.3),  
140 (femur (SD 8.3),  
138 (tibia SD 4.5),  
113(fibula, 9.6).  
 
Mean 4.4 months 
not reported not reported not reported 
Jingushi  2007 82.5%(33/40)  Not reported separately for 
DU and NU  
not reported not reported not reported 
Lerner 2004 94% (15/16) Mean bone union time 75 
weeks (34 - 224) 
not reported not reported not reported 
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Table 8.  Summary of outcomes of non-union studies 
Study Healing rate Mean Healing time Return to painless 
weight bearing 
Avoidance of 
further surgry  
Device related adverse 
events 
EXOGEN      
Mayr  2000 69% (humerus, 33/48); 
95% (radius/ulna 21/22);  
86% (femur 57/66);  
88% (tibia-fibula  105/120) 
 
Total 84% (216/256) 
174 days (humerus, SD 19.5); 
117 (radius/ulna, SD 16.1); 
157 (femur, SD 10.3);  
166 (tibia-fibula, SD 10.6) 
 
Mean 5.3 months 
no report  no report no report 
Gebauer 2005 90% (46/51) for long bones,  
85% (57/67) for all fractures.   
178 days (86- 375) for long 
bone fractures,  
168 days for all fractures.  
no report  no report  none 
Jingushi  2007 66% (21/32, not clear when the 
cut-off time point was) 
219days (56-588 for all 
delayed and non-union 
fractures) 
no report  no report no report 
Nolte  2001 100% (10/10,Tibia-tibia/fibula), 
80%(femur, 4/5),  
80% (radius-radius/ulna, 4/5),  
100% (other long bones, 2/2). 
Duration was 2 years.  
144 days(Tibia-tibia/fibula), 
185(femur),  
139 (radius-radius/ulna, 
4/5),  
153 (other long bones, 2/2) 
no report  no report None  
Romano 1999 62% (8/13 tibia, humerus, 
femur) 
95 to 181 days (3 still in 
treatment at time of report) 
no report no report no report 
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Study Healing rate Mean Healing time Return to painless 
weight bearing 
Avoidance of 
further surgry  
Device related adverse 
events 
 
SURGERY 
Bellabarba 2002 100% (20/20) 14 weeks (range 12 -20) no report  0 1 patient developed a deep 
postoperative wound 
infection. 1 patient 
developed a postoperative 
superficial frmoral deep 
vein thrombosis. Average 
estimated blood loss was 
245 milliliters (ranged 100 -
400 mililiters) 
Birjandinejad  2009 94.7 % (36/38, femur& tibia), 
100% (25/25, femoral),  
84.6% (11/13 tibia)  
4.78 months (range 1 - 6) no report  2 required 
further 
surgery 
1 wound infection 
Cacchio  2009 52%(21/41, 3 months followup), 
74%(28/38, 6 months), 
87%(33/38, 12 months),  
95% (35/37, 24 months) 
no report no report but used 
two functional 
status 
questionnaires  
no report 7% (3/42), 2 wound 
infections, 1 radial nerve 
neuropraxia.  
Khalil  2010 90% (19/21) 9.6 weeks (8 - 12) no report 2 required 
further 
surgery 
No deep infection, ulna 
neoritis and metal failure 
were recorded 
Lin  2010 95% v 93%;   18.8 v 20.1 weeks  no report 2 required 
further 
surgery 
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Study Healing rate Mean Healing time Return to painless 
weight bearing 
Avoidance of 
further surgry  
Device related adverse 
events 
Friedlaender 2001 74% (authograft) and  
62% (OP1)(bridging in at least 
three of four views) at 9 months 
followup 
no report 85%(52/61) in 
autograft group 
and 81%(51/63) in 
OP1 group  fulled 
weight bearing 
with less than 
severe pain at 9 
months followup 
10% patients 
in autograft 
group and 5% 
in OP1 group 
received 
surgical re-
treatment  
All patients experienced 
adverse events and 44% 
patients in each treatment 
group had serious event 
but none of which were 
related to their bone 
grafts. 13 arthralgia lower 
leg, 17 multiple sites pain, 
15 acute or sub-acute 
osteomyelitis lower leg, 59 
pyrexia, 37 vomiting, 26 
postoperative infection, 59 
mecgabucak complication 
of internal orthopaedic 
device, 13 hematoma 
complicating a process 
Livani  2010 100% (15/15) - Callus formation 
and cortical continuity as 
evidence of radiological union.  
9 weeks (6 - 18). Followup to 
68 weeks (12 - 68). 
no report but 
mentioned good 
functional outcome 
in all patients who 
returned to work 
with no limitations 
on daily activities.  
no No infection or any other 
clinical complications 
developed.  
Razaq  2010 91% (39/43) 5 months (SD 1.5) no report no report 3 discolor, 8 pain, 6 sweling 
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Study Healing rate Mean Healing time Return to painless 
weight bearing 
Avoidance of 
further surgry  
Device related adverse 
events 
Ring  1997 98%(41/42) 6 months (3 - 18) 41 at followup (12 - 
66 months) 
4 patients 
required 
further 
procedure 
(not very clear 
though) 
2 infections, 1 draining 
fisula 
Wu  2003 100 %(31/31) 4.5 months (median, 3 - 7.5) no report but 
stated that all 
patients could walk 
without aid 
postoperatively.  
 No deep infection, 
rotational or angular 
deformity or shortening 
reported.  
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3.7 Adverse events 
Description of the adverse events reported by the sponsor 
Does the EAC believe that the adverse events reported by the sponsor raise 
any safety concerns for the technology being evaluated? What is the opinion 
of Expert Advisers to NICE? 
The search strategy for adverse events is listed in section 10.2 (appendix 2). 
The implication is that the PubMed EXOGEN search was used to locate 
adverse events data, where ideally EMBASE, the Cochrane Library and 
MEDLINE In Process should also have been used. Additionally internal 
EXOGEN complaint databases were searched, although no further details of 
these are given.  
Under section 7.7.3 the sponsor is required to describe  all adverse events 
associated with the technology in national regulatory databases MHRA and 
FDA (MAUDE) and this has been done. Four adverse events recorded are 
described. The period April 2011 – April 2012 was searched on the MAUDE 
database but there is no explanation of why the search should be limited in 
this way. 
No device- related adverse events were reported in the EXOGEN studies 
Adverse events reported in surgery studies are listed below: 
Cacchio 2009 
The rate of adverse effects in the surgical group was 7% (three of forty-two). 
Two cases of wound infection were observed, both in the lower limb. The 
infections healed after surgical debridement and antibiotic therapy. There 
were no deep infections in this series. A radial nerve neurapraxia was noted in 
a patient in the surgical group with a non-union of the distal third of the 
humerus. 
Friedlaender 2001 
All patients in the autograft group had pain at the donor site following the 
operative procedure, and more than 80% judged their postoperative pain as 
moderate or severe. Furthermore, more than 20% of patients had persistent 
pain, mild or moderate in nature, at their 6-month visit, and approximately 
13% had persistent pain at the donor site 12 months following the operative 
procedure.  Forty-four percent of both groups had serious adverse events, 
none of which were considered related to the OP-1 implant or the bone 
autograft. Osteomyelitis was reported at the fracture site in 21% of patients 
following treatment with bone autograft but in only 3% of those receiving OP-1 
(p = 0.002).       
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Bellabarba 2002 
One case of deep infection from a patient with previous osteomyelitis and one 
case of superficial deep vein thrombosis 
Birjandinejad 2009 
No serious adverse events were reported 
 Khalil 2010 
Six patients noticed hardware prominence. Two had it removed immediately 
and one developed an ulcer which was treated conservatively prior to 
removal. No deep infection, neuritis or metal failure were recorded. 
Lin 2010 
Immediately after surgery, 43% of patients in the autograft group reported 
pain and limited mobility at the donor site. At one year 14% reported 
persistent pain or paraesthesia. No patient had deep infection, implant 
breakage, post-op fracture or heterotopic ossification 
Livani 2010 
No infection or clinical complication developed. One patient had limitations 
described as Elbow flexion deficit (10°); elbow varus (10°); shoulder elevation 
120°, moderate deficit of shoulder MR. 
Razaq 2010 
No major surgical complications were noted, although discolouration, pain and 
swelling were reported in 7%, 18.6% and 14% respectively. No other adverse 
events are reported 
Ring 1997 
There were two cases of deep infection, both occurred in patients with a 
previous infection. Five of the patients in the cohort required an additional 
surgical procedure and there was one amputation. 
Wu 2003 
No deep infections or other complications were reported 
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Description of adverse events in national regulatory databases  
The sponsor conducted a one year search (April 2011 – April 2012) of US 
FDA MAUDE database, from which they identified four recorded instances of 
EXOGEN adverse events. There were three instances of skin complaints, 
which is noted in the EXOGEN instructions for use document: 
 “Some patients have experienced mild skin irritation caused by skin 
sensitivity to the coupling gel. Resolution can be obtained by a change 
of coupling medium to mineral oil or glycerin.”  
There was one report of increased chest pain due to potential interference 
with cardiac pacemaker, which is also a stated precaution in the IFU 
 “The operation of active, implantable devices, such as cardiac 
pacemakers may be adversely affected by close exposure to the 
EXOGEN device. The physician should advise the patient or other 
person in close proximity during treatment to be evaluated by the 
attending cardiologist or physician before starting treatment with the 
EXOGEN device.” 
The sponsor noted that over this one-year period, approximately 55,000 
EXOGEN devices were used by patients in the USA. 
Review of MAUDE data from August 1995 to March 2012 submitted by the 
sponsor identified a number of other reports of localised pain or irritation, and 
one other report of a pacemaker that stopping working during use of the 
device (although, of course, it is unknown whether this was in any way related 
to use of the device). 
Overview of the safety of the technology.  
There are no significant safety concerns regarding EXOGEN in relation to the 
scope.  No device-related adverse effects were reported in the clinical studies.  
The MAUDE registry includes some reports of localised pain or irritation 
associated with use of the device, and isolated concerns over the potential for 
interference between the device and implantable devices. 
In contrast, there is well-known potential for adverse events associated with 
surgery, including the risk of infection, which can have serious consequences. 
3.8 Description and critique of evidence synthesis and meta-
analysis carried out by the sponsor 
The sponsor did not undertake any meta-analysis in their submission. They 
stated that this would not be appropriate because of the lack of controls and 
heterogeneity of outcome measurements, patient cohorts and fracture types, 
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surgery interventions, and baseline characteristics. Having reviewed the 
submitted papers, the EAC agree that any formal meta-analysis would not be 
appropriate.   
3.9 Additional work carried out by the External Assessment 
Centre in relation to clinical evidence 
We have presented a qualitative summary of the evidence above. 
3.10 Conclusions on the clinical evidence 
 There is no direct evidence comparing EXOGEN with surgery in the 
treatment of either delayed or non-union long bone fractures. 
Evidence for delayed union 
 The EAC considers that the best estimate of the absolute rate of 
healing in patients with delayed union fractures (across all long bones) 
treated with EXOGEN is 90% (87% to 92%) healed in a mean time of 
4.4 months (Mayr 2000). These estimates come from a large registry 
study that used a definition of delayed union that matched that in the 
scope, with a breakdown of results for different long bones. Other 
estimates vary and are difficult to pool because of failure to report the 
duration of follow up.  
 However, no evidence was available to estimate a comparable rate of 
healing with surgery.  It is therefore not possible to compare EXOGEN 
with surgery in this population. 
 There is some evidence to compare EXOGEN with no further treatment 
at the onset of delayed union (3 months) followed by surgery if required 
for non-union (9 months).  A sham-controlled randomised trial (Schofer 
2010), failed to detect significant improvement in the rate of healing 
with EXOGEN (hazard ratio 1.69 (p=0.07) over 4 months), although it 
did report significant improvement in indicators of progression towards 
healing (bone mineral density and bone gap area).   
 Although the comparison with placebo is not strictly relevant to the 
scope, the EAC considers that it might well be clinically appropriate if 
surgery is not usually offered until the point of non-union.  If so, then 
evidence from the Schofer trial is crucial.  This appears to be a well-
conducted study, but we note two key limitations: 
o Firstly, the trial included patients with fractures that under the 
scope definition would be defined as non-unions as well as 
delayed union fractures - approximately half the participants 
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entered the study with a fracture that had not healed in 9 months 
or longer. One might expect a greater relative risk of healing 
with EXOGEN compared with placebo in non-union fractures 
than in delayed union fractures – since, the latter may still heal 
without further intervention but the former will not. But this is 
uncertain, since healing rates with EXOGEN might also differ 
between non-union and delayed union fractures.  The 
applicability of the Schofer results to delayed union fractures is 
therefore questionable. 
o Secondly, the Schofer trial was not powered to detect 
differences in healing rates.  The primary outcomes of this trial 
were BMD and gap at fracture site (assessed by CT scan). 
 No evidence was identified for the outcomes of ‘return to painless 
weight bearing’ or ‘avoidance of further surgery’, as requested in the 
scope. 
Evidence for non-union 
 The EAC considers that the best estimate of the absolute rate of healing 
for non-union fractures (across all long bones) treated with EXOGEN is 
84% (80% to 89%), with a mean time to healing of about 5.3 months (Mayr 
2000).  These estimates come from the large registry dataset, which used 
appropriate definitions of non-union, and reported results separately for 
different long bones.  As with delayed union, estimates from other studies 
vary and cannot be pooled. 
 Estimates of the healing rate following surgery for non-union long bone 
fractures are available, but the evidence is of poor quality:  
o The sponsor reviewed surgical case series, reporting healing rates 
from 62% to 100%, and healing times from 9 weeks to 124 weeks.  
However, the included studies differed in population, intervention 
and outcome, and it is not clear that they were identified 
systematically.  
o The sponsor also cites Gebauer et al (2005), who report a mean 
healing rate of 86% based on 23 published studies of surgery in 
patients with non-union fractures (range 68% to 96%). However, 
this does not appear to be based on a systematic review, and some 
studies included non long bone fractures. 
 For the costing model, the sponsor assumes equal healing rates in non-
union patients treated with EXOGEN or surgery.  This appears to be 
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based on Gebauer et al, who compared their estimate from the literature 
with healing rates for their local registry patients treated with EXOGEN; 
also 86%.  In the absence of better information, the EAC considers that 
equal effectiveness in non-union fractures is a reasonable starting 
assumption, but it is clearly possible that healing rates could differ.  If 
EXOGEN were to be less effective than surgery at non-union, then it could 
not be dominant in this context.  We therefore tested this in sensitivity 
analysis. 
 As noted above, it might be argued that evidence from the Schofer 
placebo-controlled trial of EXOGEN could be applied to a non-union 
population.  However, the comparison is not clinically appropriate for this 
group, as they could not be left for a further four months without any 
treatment.   And without subgroup analysis, the relative risk in non-union 
patients is also uncertain. 
 No estimates of ‘return to painless weight bearing’ or ‘avoidance of further 
surgery’ were available for non-union patients treated with EXOGEN, 
although if treated successfully these patients would likely have required 
surgery if not treated with EXOGEN. 
Adverse events 
 None of the EXOGEN studies included reports of any device-related 
adverse events. There are rare reports of localised pain or irritation 
following use of EXOGEN – possibly reactions to the contact gel – and 
isolated reports of possible interactions with implantable devices. 
 Several surgery studies reported adverse events, including infections. 
The EAC did not identify any relevant clinical studies, published or 
unpublished, that were not included in the sponsor’s submission. 
Of the 19 studies listed by the sponsor, we consider that 2 are not relevant to 
the scope: as noted by the sponsor, one study initially included did not relate 
to fractures of the long bones (Pigozzi 2004); and we excluded one (Rutten 
2009) because it did not report any outcomes requested in the scope. 
The remaining studies all reported healing rates for relevant populations and 
interventions.  There was uncertainty over these reported healing rates for 
three main reasons: firstly the assessment of healing (clinical or radiographic) 
differed between studies; secondly the definitions of delayed union and non-
union varied, and were not always consistent with scope; and thirdly, the 
duration of follow-up was often unclear, making comparison of healing rates 
across studies difficult.   
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Discussion of sponsor interpretation of clinical evidence 
The sponsor provides a summary of principal conclusions from the clinical 
data (p102): 
‘EXOGEN shows heal rates of approximately 90% in delayed unions, and 
86% in non-unions, with faster progression to healing than placebo in the 
delayed union, and a similar time healing when compared to surgery (152 – 
192 days) in the case of non-union’.  
 We broadly agree with the absolute healing rates quoted for 
EXOGEN, and think that the most reliable estimates are 90% and 
84% for delayed and non-union respectively (Mayr 2000) 
 The claim that EXOGEN achieves faster progression to healing 
than placebo in delayed union is not strictly justified, since the only 
trial (Schofer 2010) also included patients who according to the 
scope definition had non-union fractures, and although intermediate 
measures of bone healing (BMD and bone gap) were significantly 
better in the EXOGEN-treated group, differences in healing rates 
were not significant. 
 It is difficult to compare rates of healing with surgery and with 
EXOGEN in non-union fractures, due to different follow-up. 
“EXOGEN treatment has no known device related adverse events” 
 Certainly, no adverse effects were reported in the included clinical 
trials, and reports of possible device-related adverse effects from 
the MAUDE database were scarce. 
 “Surgical management of non-unions in long bones produces good results 
and is an appropriate management option. The healing rates of 73% - 100% 
seen at six months in the individual trials are supported by other literature 
excluded from the searches performed.”  
 The EAC found that although most surgery studies reported high 
rates of healing, it is difficult to summarise across these studies due 
to failure to differences in length of follow-up.  
“Surgery has complications – within the individual studies the immediate 
complications are reported as DVT, infection (deep and superficial), 
haematoma and poor range of movement (ROM). Longer term complications 
included requirement for further surgery (hardware removal), persistent non-
union and in the case of bone grafting persistent donor site pain.  Even in the 
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case of achieving union of fractures through surgery, removal of metalwork 
added further surgical intervention to patient management  “ 
 We agree that some major complications were reported in the 
surgery studies. 
It was also asserted that for EXOGEN: 
 ‘A reduced time to healing compared with surgery, particularly with reference 
to delayed union’.  
 The foundation for this statement is unclear, as no direct or indirect 
evidence was presented for surgery in delayed unions.  
 “The avoidance of surgical intervention to achieve comparable clinical 
outcomes.  Similar healing rates and time to healing are reported.” And 
“Use of the EXOGEN ultrasound bone healing system may reduce the need 
for high cost surgical intervention. Assuming the heal rates reported, 
EXOGEN has the potential to reduce 86% of the operations that are currently 
performed on stable, well-aligned delayed or non-union fractures 
 The EAC agrees that there is the potential for cost savings, and 
avoidance of complications, if EXOGEN were to reduce the need 
for surgery. 
 There is no direct clinical evidence that early use of EXOGEN in 
delayed union would avoid rates of further surgery.  However the 
EAC notes that there is indirect evidence for this claim, based on 
intermediate healing outcomes (outside the scope) in a mixed 
delayed union and non-union population. 
 Similarly in non-union, there is no direct comparative data 
supporting the claim that EXOGEN would reduce rates of surgery.  
There is indirect evidence from case series, showing broadly 
comparable rates of healing, although differences between the 
studies make this difficult to interpret.  If surgery was more effective 
in this population, it is possible that the use of EXOGEN would 
further delay definitive treatment.  
“There is less clarity regarding the impact of EXOGEN on a quicker return to 
weight bearing and normal daily living as compared with surgery.” 
 We agree, as no evidence was found  for these outcomes with 
EXOGEN, and no comparative data in relation to surgery. 
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4 Economic evidence 
4.1 Published economic evidence 
Critique of the sponsor’s search strategy 
The search methods for economic evidence are detailed in section 8.1 of the 
submission and details of the strategies are appended in section 10 Appendix 
3. The strategy was run on PubMed only. A broader strategy using MEDLINE 
and EMBASE combined with economic filters would have been advisable. 
The EAC recreated the sponsor’s strategy and ran it on EMBASE to establish 
whether any relevant studies had been missed. 
The sponsors did not search NHS EED or EconLit as recommended. 
However the EAC tested this and can confirm no additional relevant studies 
were found by searching these two databases. 
A minimal economic filter (economic* or cost*) was used in combination with 
the EXOGEN and Surgery strategies discussed previously to pinpoint relevant 
economic evidence. Truncation of these two terms was not used in the 
EXOGEN search which may have narrowed the search slightly.  A more 
detailed economic filter may have located additional relevant literature. The 
EAC tested a filter of this type on MEDLINE and located 170 studies although 
this sensitivity would have been to the detriment of precision in the search (a 
lot of irrelevant papers to be screened to locate any extra relevant ones). In 
addition we might assume that economic studies would have been set aside 
during the sponsor’s screening process, serving as an internal “filter”.  
The searches were again limited to English language only. The EAC searches 
did not impose this limit to test whether any studies may have been missed in 
this way.  As with the searches for clinical evidence a date limit of 1992-2012 
was used. 
The sponsor again used cited reference searching to identify additional 
studies.  
Internal Smith and Nephew databases and Google searching were also used 
to locate unpublished material. 
The results of the economic searches are illustrated in a flow chart (fig. 6). 6 
studies were identified from “other sources” – possibly the methods described 
above but this could be made more transparent. 
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Critique of the sponsors study selection 
The sponsor used specified inclusion and exclusion criteria to select health 
economic studies for inclusion in their review.  The criteria were consistent 
with the scope, and also with those used to select clinical evidence. 
Included and excluded studies 
The sponsor included three economic studies (see Table 9).   
Table 9.  Included economic studies 
Study  Design Population Intervention(s) 
Taylor 
2009 
UK Cost effectiveness 
analysis - Markov 
model using 
published data 
Fresh and non-
union tibia 
fractures 
Fresh: Casting, IM 
nailing, EXOGEN and 
casting (for fresh 
fractures). 
NU: Exogen vs. Surgery 
Kanakaris 
2007 
UK Cost study 
(secondary) 
Non-union 
fractures of 
humerus, 
tibia, femur 
Surgery 
Patil 2006 UK Cost study (audit of 
41 cases) 
Non-union of 
tibia and 
femur 
Surgery 
 
Overview of methodologies of all included economic studies 
One study (Taylor 2009) was a cost minimisation study, estimating the net 
cost of alternative treatment strategies for patients with fresh (out of scope) 
and non-union fractures of the tibia.  The analysis was based on a Markov 
model, with monthly cycles over a time horizon of one year.  The non-union 
analysis compared EXOGEN with surgery.  Parameter estimates were 
obtained from published sources.   
The other two studies (Kanakaris 2007 and Patil 2006) were non-comparative 
analyses, estimating the cost of surgical treatment for patients with non-union 
fractures of long bones. 
Overview and critique of the sponsor’s critical appraisal 
The economic studies were reviewed using the BMJ checklist for appraising 
economic evaluation studies (Drummond and Jefferson 1996).   
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Does the sponsor’s review of economic evidence draw conclusions 
from the data available?  
The submission included a summary of the findings of the three studies.  
Taylor et al concluded that for non-union fractures, the dominant strategy is to 
delay surgery and try a course of ultrasound therapy first.  Based on 
published literature they concluded that this would give an equivalent healing 
rate to immediate surgery, at lower cost (£6718 for surgery compared with 
£3926 for EXOGEN).  The model developed for this published paper was 
adapted for use in the submission. 
Kanakaris et al estimated the total cost of treating aseptic non-union long 
bone fractures, using ‘gold standard’ treatment over a six month period. They 
estimated the cost of treating humerus, femur and tibia fractures at £15,566, 
£17,200 and £16,330 respectively. 
Patil et al conducted a ‘bottom up’ costing for 41 complex non-union tibia or 
femur fractures treated surgically with the Ilizarov procedure.  The estimated a 
mean cost per patient of £29,204. 
 
4.2 De novo cost analysis 
Patients 
Two cost models were submitted by the sponsor: one for non union and one 
for delayed union (adapted from the model by Taylor et al, mentioned above).  
Both analyses were restricted to fractures of the tibia.  The submission 
highlighted the complexity involved in creating a cost model for each fracture 
site, lack of good sources of data and the high incidence of healing problems 
in tibial fractures as reasons for focusing on this group. 
We note that the results from these analyses are not necessarily 
generalisable to other long bones.  Nevertheless, expert opinion suggests that 
the tibia might offer a reasonable reflection of likely costs in fractures of other 
long bones. The submitted models could potentially be adapted for other long 
bone fractures.   
Technology 
 Delayed union: EXOGEN Express at diagnosis of delayed union, 
followed by surgery if the fracture does not heal within 6 months (9 
months post fracture).  
 Non union: EXOGEN 4000+ at diagnosis of non-union, followed by 
further surgery if the fracture does not heal within six months. 
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Comparator(s) 
 Delayed union: no further intervention at diagnosis of delayed union, 
followed by surgery if the fracture does not heal within 6 months (at 
non-union). 
 Non union: Surgery at diagnosis of non-union, followed by further 
surgery if the fracture does not heal within a further 6 months. 
Model structure 
The overall schematic provided in the submission (Figure 7) seems to 
accurately represent the clinical pathway of care, although there are some 
issues around the translation of this into excel format for analysis.  
Interpretation of the modelling was hampered somewhat by the failure to 
provide separate diagrams for the delayed union and non union models. 
A Markov model, with a time horizon of one year and monthly cycles was 
used to conduct the cost analysis. Markov diagrams showing the health states 
and transitions included in the delayed union and non-union models are 
shown below. 
Delayed union model 
There are 5 health states, and all members of the cohort begin in the delayed 
union state. It is assumed that surgical intervention (IM nailing) has occurred 
previous to delayed healing, shortly after the fracture.   
Figure 2.  Model structure for delayed union 
 
 
Delayed 
union 
fracture 
Healed 
fracture 
Non union 
fracture 
Post 
infection 
Infection 
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The model is run twice: once for the EXOGEN arm, where patients start using 
the EXOGEN Express device at the beginning of the modelling period; and 
once for the control arm, where patients are assumed to have no further 
treatment (observation only) until the time of non-union.  
In subsequent cycles, patients can move to healed (an absorbing state), 
infection, or after six-months in the model, to non-union.  Following infection a 
staged revision surgery process begins, with the administration of intravenous 
(IV) antibiotics and removal of metalwork. It is considered that the infection 
will take a minimum amount of time to clear up (2 months) at which point 
revision surgery will take place. Patients can become re-infected having 
previously moved into the post infection state.   
After six months of a delayed union fracture not healing and no infection 
occurring, the patient progresses to non union fracture, where further surgery 
takes place.  In subsequent cycles, non-union patients may heal or acquire an 
infection.   
The submitted model assumes that there is a minimum time to heal of 2 
months from baseline in both arms, but this does not seem realistic, given that 
the initial surgery will have taken place 3 months previously – this appears to 
be a left over assumption for the earlier version of the model designed for 
evaluation of treatments for fresh fractures.  Conversely, the submitted model 
did not assume any minimum time to healing following revision surgery after 
six months.  
Non union model 
The Markov model for non union fractures can be characterised in a similar 
fashion, but all patients begin in the non union fracture health state. Patients 
in the EXOGEN arm receive treatment with the ultrasound technology from 
baseline, whilst patients in the comparator arm receive surgery at baseline.  
In both arms, if healing has not occurred after six months in the non union 
fracture health state, it is assumed that further surgery is performed.  
In the surgery arm, patients are at risk of infection from the onset of non-union 
and also if they have further revision surgery after six months in the non-union 
state.  However, the submitted non-union model assumes that no infection 
can occur in the EXOGEN arm.  This seems appropriate for the first six-month 
period, when patients in this arm have not been recently exposed to the risk of 
infection from surgery (they last had surgery 9 months previously for a fresh 
fracture).  However, it does not seem correct for patients who fail to heal after 
a 6 months in the non-union state.  
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Figure 3.  Model structure for non-union 
 
The non-union model assumes a 2-month minimum time to healing from the 
start of EXOGEN treatment, and initial surgery.  However, it does not apply 
this same delay after revision surgery at 6 months. 
Clinical parameters and variables 
Clinical parameters in the model come from a variety of sources as outlined in 
section 9.2 of the submission.  
Monthly healing rates, converted from 6 month rates, are used to determine 
transition from delayed union and non union health states into the healed 
state. In the delayed union model, the healing rate in the EXOGEN arm is 
based on the 65% healing at 16 weeks from Schofer (2010) and that in the 
Surgery arm is based on 92% healing (tibia/tibia-fibula) at approximately 4 
months in Mayr (2000).  These rates were extended over a 6 month period by 
assuming a simple linear assumption (e.g. 69% healed over six months = 
65% *6/4) 
In the non-union model, healing rates for both the EXOGEN and surgery arms 
come from Gebauer et al (2005), estimated to be 86% for 6 months. 
The models use an infection rate of 1.4%, based on a 2011 HPA report inform 
transition from delayed and non union states into infection. This rate was 
calculated from 7,580 cases of reductions of long bone fracture where 104 led 
to readmissions. This rate is applied as a monthly rate in the submitted 
models and the EAC questions the validity of this approach. It would be more 
appropriate to have applied this as a one-off probability in the first month after 
infection, given that the median and inter quartile range time to infection in the 
HPA data falls within the first month, and to do a sensitivity on a higher rate.   
The sponsor used expert advisers to provide a check of face validity of 
modelling and the clinical pathway defined. They also offered validation of 
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model inputs and in particular resource use.  However, the submission does 
not give any details about how this expert opinion was elicited.  
The time horizon chosen for both models was one year. There seems to be 
little justification as to why this is the case, but for both models this does lead 
to a majority of fractures having healed by the end of the time period.  
Resource identification, measurement and valuation  
Resource use was identified from the clinical pathway defined in section 9.1.4 
of the submission. For surgical interventions, the resource use involved in the 
procedures was broken down into individual components, to each of which a 
unit cost was applied, to construct a total cost. Estimates of resource use 
were informed by clinical opinion, and it is not clear how this was elicited, or 
whether published data might have been available to inform these estimates. 
The process involved in dealing with infection was taken from Cierny (2003) 
and resource use identified from a range of sources including expert opinion. 
Information from the NICE hip fracture guideline (CG124) is used to inform the 
components of theatre time and bed stay.  The EAC questions whether these 
estimates are reflective of usual care for patients with long bone fractures, 
due to the different demographic of patients with hip and long bone fractures 
and their different clinical needs. In Taylor (2009) they identify that the 
antibiotics administered to patients with an infection can be delivered on an 
outpatient basis, which is less costly than the IV inpatient antibiotics assumed 
in the sponsor’s submitted cost models. The EAC would also suggest that 
there might be some routinely available reference costs that could be used, 
which would provide good costs estimates applicable to the NHS. This could 
be explored as a sensitivity analysis. 
The estimates of resource use for routine observations applicable to the 
health states in the model are not clearly outlined. There is no reference to the 
source of this information. The valuation of resource use that occurs in each 
health state was provided from published sources where possible. 
Physiotherapy costs are taken from NICE guideline CG124, the cost of a GP 
visit and wheelchair from Curtis (2010), and an outpatient visit from NHS 
reference costs. The cost of crutches and an X-ray were acquired from expert 
opinion. The EAC feels that for the latter especially, a more robust estimate 
could be gained from published sources. 
The submission states that non procedure costs are the same in both arms.  
Although unit costs are the same, the resources used in the non union model 
actually differ between the arms. This has the effect of increasing the costs of 
each health state in the Surgery arm (in all health states by £100). 
Furthermore, in Table C7 of the submission (p.137) health state costs for “not 
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healed, not infected” health states are said to be £255. This cost is not used 
at any stage in the modelling. In the excel model, depending on which of 
health states the patients are in, the value of this differs and the submission 
does not suggest this is the case. 
Unit costs included in the model for non union surgery, revision surgery and 
staged revision were estimated using a micro-costing approach to incorporate 
different components of cost. The unit costs and their sources are displayed 
below.  Again, the EAC suggests that Reference Cost data might be a more 
suitable source for an estimate of the cost of surgery. 
Costs used in submitted models 
Surgery- £3,437 
 NICE Guideline CG 124 unless otherwise stated 
 4.9 days bed stay (HES W28.1) - £1184.28 
 3 hours surgery - £957 
 1 pre-op prophylaxis antibiotic= £14.50 
 BNF - Injection, powder for reconstitution, vancomycin (as 
hydrochloride), for use as an infusion, 1-g vial   
 Long IM nail - £1175.40 
 Iliac bone graft - £106.33 (additional 20 min theatre time) ref 45 St. 
John (2003) 
GP visit-£41 
 Curtis L (2010). Unit Costs of Health and Social Care 2010. 
Personal Social Services Research Unit: University of Kent. 
 Table 10.8b: General Practitioner - unit costs. 
 Per clinic consultation lasting 17.2 minutes, excluding direct care 
staff costs, without qualification costs. 
Outpatient visit- £137 
 NHS Reference Costs 2012-2013. 
 NHS Trusts Outpatient Attendances 
 110T - Trauma & Orthopaedics: Trauma 
Cost of treatment of infection (including revision surgery) – 
£14,527 
 Staged admission and treatment for chronic osteomyelitis: 
 Removal of implant and debridement = 3 hours theatre (expert 
opinion) = £957 (NICE CG124) 
 Temporary fixator = £1050 (personal communication Smith & 
Nephew) 
 Minimum 21 days bed stay = £5075.49 (NICE CG124) NHS trust 
communication infection control guidelines 
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 IV antibiotic (source NHS prescription services May 2012, 
Flucloxacillin 1g powder= £4.90 per vial, 8g per day) = £823.00 
Assuming cleared infection: 
 Further 3 hours surgery = £957 
 Antibiotic Prophylaxis = £14.50 
 Synthetic bone graft and /or DBM = £448 (data on file idata 
Orthopaedic biomaterials report) 
 Simple external ring fixator = £2,520 (personal communication 
Smith & Nephew) 
 Average 11.1 days bed stay (W.30.4 apllication of external ring 
fixation to bone, NEC) = £2682.76 
 Total = £14,527 
Note - this estimate is much higher than that in the Taylor et al study 
(which was based on HRG costs).   
The sponsor notes two published cost estimates: 
 Patil 2006 (ref 34) describes limb salvage procedure costs to be 
approximately £30,000 
 Thakar 2010 (ref 36) states mean cost of treating deep infection is 
£22,846 
However, these relate to particularly complex cases are not reflective of 
mean costs across the all cases. 
Drugs for infection-£50 expert opinion 
Cost of X-ray- £70 expert opinion 
Wheelchair (per month)- £14 
 Curtis L (2010). Unit Costs of Health and Social Care 2010. 
Personal Social Services Research Unit: University of Kent. 
 Table 7.2: NHS Wheelchairs 
 Unit cost per active user per chair per year. 
Crutches- £35 
 Based on expert opinion from 2005, inflated to 2010 prices. 
Physiotherapy- £200 
 NICE guideline 124  
 Combination of Physiotherapy and Occupational therapy 
 Health Economics report - Appendix H table 98 
 8.5 hours per patient p. 572 
   53 of 151 
External Assessment Centre report: EXOGEN 
Date: 22
nd
 June 2012 
 
Technology and comparators’ costs 
Cost of EXOGEN used in the models differed from that stated in the sponsor 
submission. 
EXOGEN 4000+ (non union)-  £2,562.50 +VAT-  Smith & Nephew 
 
 @20% VAT  = £512.50 
 Total cost = £3,075 
 Cost of EXOGEN used in modelling £2,667 
EXOGEN Express (delayed union) = £999.38- Smith &Nephew 
 @ 20% VAT = £199.88 
 Total cost =  £1,199.26 
 Cost of EXOGEN express used in modelling = £998 
 
Sensitivity analysis 
The submission includes details of deterministic sensitivity analysis carried 
out to explore parameter uncertainty and the effect this has on the 
incremental cost of EXOGEN. One way and two way analyses were 
conducted varying the healing rates for EXOGEN and Surgery.  The rate of 
infection was also varied.  
For EXOGEN, values for the healing rate were used to reflect a 10% or 20% 
reduction compared with the base case. For surgery, healing rates were 
increased by 5% and 10%.  By varying the values either alone or in 
combination, “best” and “worst” case scenarios are examined. 
It is not clear why these values were chosen, nor is it clear why they were not 
uniform across the two groups, giving very arbitrary analysis. It would have 
been more appropriate to base the sensitivity analysis on the range of results 
reported in included studies.  The submission does however test the impact of 
varying the healing rate across a fairly large range to explore the sensitivity of 
base case results to changes. 
The Infection rate was varied from the base case value of 1.4% to 5.1%, and 
justification of this was not provided, though it may bear relation to the rate 
noted for high risk patients such as smokers (Castillo 2001). 
There were few details provided around what might be considered another 
important set of variables in the model- costs inputs. Although in isolation 
   54 of 151 
External Assessment Centre report: EXOGEN 
Date: 22
nd
 June 2012 
changing one of these, e.g. cost of surgery might have a small impact; 
incorporating uncertainty in a multi-way analysis might show greater 
sensitivity.  
It is stated that “The model was relatively insensitive to variation in all other 
parameters”, but these wider sensitivity analyses were not presented in the 
submission. 
4.3 Results of de novo cost analysis 
Base-case analysis results 
Results from the sponsor’s basecase models are reported in Table 10 and Table 
11 below, for delayed union and non-union respectively.  These results 
suggest that EXOGEN is cost-saving in both contexts.   The EAC confirmed 
that the results reported in the submission match the output of the submitted 
models. 
 
Table 10  Base case analysis results: delayed union model 
Intervention Mean cost per patient 
EXOGEN Express £4,290 
Control (routine observation) £4,974 
EXOGEN vs control -£684 
 
 
Table 11  Base case analysis results: non-union model 
Intervention Mean cost per patient 
EXOGEN 4000+ £4,647 
Surgery £6,957 
EXOGEN vs Surgery -£2310 
 
Sensitivity analysis results 
The sponsor varied the healing rate with EXOGEN and with surgery and also 
the rate of infection in sensitivity analysis.   
 Non-union model: The findings were relatively insensitive to the 
parameter changes tested.  EXOGEN remained cost saving for non-
union in all scenarios tested.   
 Delayed union model: EXOGEN ceased to appear cost-saving when 
the difference in healing rates between EXOGEN and the control arm 
was reduced.  In the base case, the six-month healing rates were 
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assumed to be 69% for the control group and 92% for EXOGEN.  
When the rate for EXOGEN was reduced to 82.8%, its estimated cost 
was very similar to that of the no intervention control.  And if the 
difference was further reduced, EXOGEN became more expensive 
than the control. 
The EAC re-ran these sensitivity analyses, and confirmed that the results 
were consistent with those reported in the submission. 
Subgroup analysis 
Not reported 
Model validation 
The sponsor notes that the submitted models are adaptations of a published 
model (Taylor 2009), and was subject to peer review as part of the publication 
process.  They note that the model was also subject to ‘internal validation’, 
and that the clinical pathways were derived through consultation with expert 
clinical advisors, but no details are given.   
4.4 Interpretation of economic evidence  
The sponsor quotes the conclusion for the published cost analysis (Taylor 
2009), on which the submitted models are based: 
” From an NHS perspective, adjunctive ultrasound offers a cost-effective 
choice for patients at particular risk of non-union, and for non-union 
fractures which are stable and well-aligned.”  
The sponsor goes on to claim that “the de novo analysis, based on updated 
treatment costs and revised infection rates supports this conclusion.  Any 
assumptions adopted in the analysis are believed to be conservative, 
suggesting that the potential savings presented may be underestimated.” 
(p152). 
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4.5 Additional work undertaken by the External Assessment 
Centre in relation to economic evidence 
The EAC reviewed the assumptions built into the sponsor’s model in relation 
to available evidence and expert opinion.  We considered that a number of 
assumptions are not justified.  By reviewing the Excel formulae, we also 
identified a number of what we consider to be errors in the coding of the 
model.  We summarise below the changes that we made to the submitted 
models, and how we tested them in sensitivity analysis. 
Costs 
 The prices entered in the spreadsheets differed from those stated in 
the submission.  We have confirmed that the correct prices are 
£2,562.50 + VAT for EXOGEN 4000+ and £999.38 + VAT for EXOGEN 
Express.  
 VAT was not added to the prices in the model, and depending on the 
perspective this may or may not be appropriate.  We conduct a 
sensitivity analysis in which we add VAT both to the cost of EXOGEN 
and to other consumables in the model. 
 As noted previously, the submission indicates a health state cost of 
£255 for individuals who are “not healed-not infected” and that costs do 
not differ between arms (p137). The models however have different 
cost for delayed union and non union patients in this state based on 
resource estimates in the model. Not knowing the combination of 
resource usage that yields £255 per month, we have used the resource 
use already stated in the model.  In the non union model these health 
state cost also differ between arms.   We understand that these 
differences were not intended, and have corrected them (assuming one 
day per month physiotherapy for both EXOGEN and surgery arms). 
 The cost of surgery in the submitted models is estimated by a ‘bottom 
up’ costing based on expert opinion about the likely use of resources.  
The EAC maintained the sponsor’s estimate of the cost of surgery 
(£3,437) in our main analyses, but tested the effect of using Reference 
Cost estimates in sensitivity analysis: with a lower estimate of the cost 
of surgery £2,349 (weighted mean of HRG codes HD24A, HD24B 
elective with CC/with major CC); and an upper estimate of £4,126 
(HRG code of HA99Z). 
Healing rates for delayed union model 
 The methods used to calculate healing rates from the clinical data are 
not explained in the submission.  We understand that in the delayed 
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union model, the 6-month healing rate for the control arm is taken from 
the control arm of the Schofer trial, multiplied by 6/4 to adjust it from 4 
to 6 months (0.46*6/4=0.69).  A more appropriate method for 
extrapolating this data would be to assume a constant hazard rate. 
 The healing rate for the EXOGEN arm in the delayed union model is 
taken from the Mayr registry paper (92% for tibia/tibia-fibula delayed 
union fractures at a mean follow up of 138 days).  This figure was not 
adjusted from the average 4.5 months to six-months.   
 No justification is given for using two separate data sources, rather 
than the comparative evidence that is available from the Schofer trial.  
A direct comparison of 4-month healing rates from the trial would give 
0.46 for the control arm versus 0.65 for the EXOGEN arm.  This 
appears reasonable for the comparison in the delayed union model, 
although approximately half of the patients in the Schofer trial would be 
classified as non-union cases, based on the definition in the scope. 
 An alternative approach would be to take the baseline healing rate with 
EXOGEN from the Mayr paper (0.92 at approximately 4 months), 
dividing by the relative effect for EXOGEN vs no further treatment from 
Schofer (hazard ratio 1.69) to yield an indirect estimate of the healing 
rate without EXOGEN (0.78).  The EAC considers this to be a more 
appropriate approach, as the population from the registry is more likely 
to be applicable to the general delayed union population.  However, we 
conduct a sensitivity analysis using the Schofer data for both arms. 
 The delayed union model includes an assumption that there is a 
minimum time to healing, though this is not discussed in the 
submission.  Following expert advice, we assume that this should apply 
following surgery (which in this model may occur for patients in either 
arm who have not healed by 9 months).  We conduct sensitivity 
analysis to test the impact of removing this minimum time to healing 
assumption. 
 A final assumption that we make is about the onset of the effects of 
EXOGEN on healing (applying a similar 2 month delay in the benefits 
of EXOGEN as for surgery), and in the persistence of the effects of 
EXOGEN after treatment has been completed at 4 months.  Again, we 
test the impact of these assumptions in sensitivity analysis. 
Healing rates for non-union model 
 The non-union model assumes equal healing rates for surgery and 
EXOGEN based on the Gebauer paper.  We accepted this as a starting 
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assumption, but tested the impact of changing the relative risk of 
healing for surgery compared with EXOGEN – given the lack of 
comparative evidence on this point.   
 In our main analysis, we take the healing rate for EXOGEN from the 
Mayr registry data (88% for tibia/tibia-fibula fractures over 
approximately 6 months).   
 We noted and rectified that the non-union model contains an error in 
months 7, 8 and 9, when the total number of people in the cohort 
increases above the initial 1,000.   
Infection rates and costs 
 In our main analyses, we used an estimated post-surgical infection rate 
of 2.6%.  This reflects reported infections (74 cases) identified during 
the inpatient stay or subsequently through readmission following 
operations for reduction of long bone fractures in 2864 patients at 
raised risk of infection (index score 1-3) (HPA 2011, Table 2 p9). 
Though unlikely to capture all surgical site infections, it is also very 
unlikely that this rate would recur for every month post surgery.  We 
therefore include this as a one-off rate of infection following any 
surgery in our main analyses. 
 Taylor et al (2009) estimate the risk of infection based on an analysis of 
Medicare claims data.  This gave an annual rate of osteomyelitis as 
4.95%, which equates to approximately 0.42% per month. We used 
this as a recurring monthly rate after surgery, as an alternative to the 
one off 2.6% HPA rate. 
 The sponsor’s non-union model assumed that there is no risk of 
infection in patients treated with EXOGEN, which might be appropriate 
for the first six months (as patients in this arm do not have further 
surgery during this time).  But it is not justified for patients whose 
fractures do not heal with EXOGEN and who go on to have revision 
surgery after a further six months. 
 The sponsor’s models use a bottom-up costing approach to estimate 
the NHS cost of treating infections.  This assumes that all patients with 
an infection have a ‘deep’ or ‘major’ infection, such that they require 
intravenous antibiotics, incurring a 3 week inpatient stay in addition to 
the costs of revision surgery: total cost £14,527 (p138).  This appears 
at odds with estimates from the HPA report (Figure 4, p15), which 
indicates that 48.7% of infections following reduction of long bone 
fracture are ‘superficial’. The published version of the model (Taylor et 
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al 2009), assumed that after an initial inpatient stay, patients with an 
infection could be discharged and complete the antibiotics on an 
outpatient basis (estimated at £3,210 in 2006 prices).  This seems to 
be a more realistic estimate, as least for those patients with superficial 
infections.  We therefore estimated a cost of infection comprising 
£14,527 for the 51% of patients with deep infections, and an updated 
reference cost value (£3,109 for HRG code HD23) for the remaining 
49% with superficial infections. 
4.6 Results of EAC sensitivity analysis 
EAC results - Non Union 
The following changes were made to the submitted non-union model: 
 Healing rates taken as 88% after 6 months from Mayr. 
 Relative risk for surgery compared with EXOGEN = 1.0 
 Two-month minimum time to healing for both EXOGEN and surgery at 
baseline, and for further surgery at 6 months 
 Removal of double counting of individuals in months 7,8 and 9. 
 Allowing infection in EXOGEN arm following surgery at 6 months. 
 Changing costs to reflect non union resource use at baseline, rather 
than that of fresh fracture. 
 Price of EXOGEN changed from £2667 to £2562.50 
 Infection rate 2.6% in first month following surgery (at 9 months post 
fracture for the surgery arm, and for both groups if they have not 
healed after a further six months) and 0% up until repeat surgery 
 Cost of infection weighted using for £14,527 for 51% deep infections 
and HRG £3,108 for 49% superficial infections = £8,932. 
 Resource use - physiotherapy same between arms. 
The results of this analysis are shown in Table 13 below.  This suggests that 
EXOGEN would be cost saving compared with immediate surgery for non-
union. 
Table 12.  EAC main model non-union: mean cost per patient  
Model EXOGEN  Surgery  Cost difference  
EAC main analysis £5,688 £6,852 -£1,164 
 
There is uncertainty over the relative healing rate for surgery compared with 
EXOGEN.  We therefore tested this in sensitivity analysis (Table 13).  This 
shows that the magnitude of the estimated cost savings declines as surgery 
becomes more effective than EXOGEN.  However, even if the healing rate 
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with surgery is over twice that with EXOGEN, the latter still appears to be cost 
saving.  This is because EXOGEN is considerably cheaper than surgery. 
Table 13.  EAC non-union model: varying RR surgery compared with EXOGEN  
Relative risk EXOGEN  Surgery  Cost difference  
(EXOGEN - Surgery) 
0.5 £5,688 £8,309 -£2,621 
1.0 £5,688 £6,852 -£1,164 
1.5 £5,688 £6,274 -£586 
2.0 £5,688 £6,029 -£341 
2.5 £5,688 £5,915 -£227 
 
We conducted a two-way sensitivity analysis, varying the baseline healing 
rate with EXOGEN (95% confidence interval from Mayr 2000 study) and the 
relative risk of healing with surgery compared with EXOGEN.  This results are 
quite stable, only if we reduce the healing rate with EXOGEN to its lower limit, 
and the relative risk of healing with surgery to its upper limit does EXOGEN 
become more expensive than surgery. 
Table 14.  EAC non-union model: baseline healing rate with EXOGEN and RR with surgery  
 Cost difference per patient (EXOGEN – surgery) 
Relative risk 
surgery vs EX 
EX Lower CI EX Mean rate EX Upper CI 
82% 88% 93% 
0.5 -£2,692 -£2,621 -£2,448 
1.0 -£1,167 -£1,164 -£1,160 
1.5 -£465 -£586 -£749 
2.0 -£129 -£341 -£598 
2.5 £40 -£227 -£532 
 
Other sensitivity analyses conducted on the non-union model are reported in 
Table 15.  EXOGEN remained cost-saving in this context under all scenarios 
tested.   
 
Table 15.  EAC non-union model: other sensitivity analysis  
Sensitivity analysis EXOGEN  Surgery  Cost difference  
(EXOGEN - Surgery) 
No delay in onset of healing £5,046 £6,224 -£1,178 
VAT on devices and consumables £6,199 £7,123 -£924 
Annual risk of infection 4.9% £5,652 £6,734 -£1,082 
HRG cost of infection (£3,108) £5,635 £6,638 -£1,002 
HRG cost of surgery (£2,350) £5,527 £5,601 -£74 
HRG cost of surgery (£4,126) £5,735 £7,589 -£1,854 
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EAC results - Delayed Union 
The following changes were made to the delayed union model: 
 Allowing infection in EXOGEN arm following further surgery for patients 
who have not healed after 6 months (9 months post-fracture) 
 Changing costs to apply to delayed union resource use (as per model) 
at baseline, not fresh fracture. 
 Price of EXOGEN changed from £998 to £999.38 
 Infection rate 2.6% in first month following surgery (for patients in both 
arms whose fractures fail to heal by 9 months post-fracture) and then 
0% in subsequent cycles 
 Cost of infection weighted using for £14,527 51% deep and HRG 
£3,108 for 49% superficial = £8,932. 
The EAC estimated results for eight scenarios reflecting different sources of 
healing rates (Mayr for EXOGEN and relative risk from Schofer vs. Schofer 
alone), and different assumptions about the minimum time to healing following 
surgery and EXOGEN (no delay vs. two-month delay before healing is 
observed), and the persistence of relative benefits of EXOGEN (persistence 
vs. no persistence of enhanced healing rate between end of EXOGEN 
treatment at 4 months and further surgery if needed at 6 months).  
Model 1 
Assumes healing rate with EXOGEN of 92% at four months (Mayr) and 
hazard ratio for EXOGEN versus placebo 1.69 (Schofer) 
A- 2 month delay, no persistence of benefit of EXOGEN beyond 4 months  
B- 2 month delay, persistence of benefit of EXOGEN beyond 4 months 
C-  No delay, no persistence of benefit of EXOGEN beyond 4 months  
D- No delay, persistence of benefit of EXOGEN beyond 4 months 
Model 2 
Uses Schofer healing rates for both arms: 46% for controls and 65% for 
EXOGEN group over four months. 
A- 2 month delay, no persistence of benefit of EXOGEN beyond 4 months  
B- 2 month delay, persistence benefit of EXOGEN beyond 4 months 
C-  No delay, no persistence of benefit of EXOGEN beyond 4 months  
D- No delay, persistence of benefit of EXOGEN beyond 4 months 
The monthly and cumulative healing rates for these scenarios over the 12 
month time horizon are shown in Figure 4 and Figure 5.
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Figure 4.  EAC delayed union models 1A to 1D: EXOGEN healing rate (Mayr), hazard ratio (Schofer) 
 
   63 of 151 
External Assessment Centre report: EXOGEN 
Date: 22
nd
 June 2012 
Figure 5.  EAC delayed union models 2A to 2D: healing rates for both groups from Schofer 
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Our preferred scenario is model 1A because we believe that:  
a) the best estimate of the healing rate with EXOGEN is the registry 
data reported by Mayr et al;  
b) the best estimate of relative healing rates with EXOGEN compared 
with no further treatment until non-union is the Schofer trial; 
c) it is reasonable to assume that healing following surgery or start of 
EXOGEN treatment will not usually be observed within two months 
(clinical opinion); 
d) it is conservative to assume that EXOGEN does not continue to 
enhance the background healing rate once ultrasound treatment has 
finished after four months (the duration of follow-up in the Schofer trial). 
Results for the main EAC analyses for delayed union fractures of the tibia are 
shown in Table 16. Under the EAC preferred model (1A), using EXOGEN at 
this time point is estimated to be about £500 more expensive per patient than 
waiting and treating surgically at non-union if necessary.  For most scenarios, 
EXOGEN is not cost saving in this context.  The only real exception is with 
model 2B: where we assume that healing with EXOGEN is not observed until 
month 2, that it climbs quickly to 65% at four months, and continues at this 
faster rate until month six (when any remaining unhealed patients have 
surgery). 
Table 16.  EAC main analysis delayed union: mean cost per patient 
Model EXOGEN Control 
(placebo) 
Cost difference  
(EX vs control) 
Healing rates at four months: 92% EXOGEN (Mayr), RR 1.69 (Schofer) 
1A  delay  no persistence £3,033 
 
£2,529 
 
£504 
 1B  delay  persistence £2,899 
 
£2,529 
 
£370 
 1C no delay  no persistence £2,835 
 
£2,384 
 
£451 
 1D no delay persistence £2,772 
 
£2,384 
 
£388 
 Healing rates: 65% EXOGEN and 45% control (Schofer) 
2A  delay  no persistence £4,674 
 
£4,571 
 
£103 
 2B  delay  persistence £4,181 
 
£4,571 
 
-£390 
 2C no delay  no persistence £4,212 
 
£4,024 
 
£188 
 2D no delay persistence £4,009 
 
£4,024 
 
-£15 
 
Table 17 shows the results of a two-way sensitivity analysis on the EAC 
preferred model (1A), in which we vary both the baseline healing rate with 
EXOGEN (between 95% confidence limits from Mayr) and the relative risk of 
healing with EXOGEN compared with control (from Schofer).  Results are not 
sensitive to these changes, and EXOGEN remains more costly than waiting to 
see if the patient heals without further intervention. 
   65 of 151 
External Assessment Centre report: EXOGEN 
Date: 22
nd
 June 2012 
Table 17.  EAC delayed union: sensitivity analysis on healing rate with EXOGEN and RR 
Relative risk 
(Ex vs control) 
Cost difference per patient (EXOGEN – control) 
EX lower CI EX mean rate EX upper CI 
89% 92% 95% 
1.0 £999 £999 £999 
1.7 £405 £504 £621 
2.0 £114 £239 £395 
 
Other sensitivity analyses on version 1A of the EAC model are presented in 
Table 18.  EXOGEN remained more expensive than the comparator under all 
of the scenarios tested. 
Table 18.  EAC delayed union: other sensitivity analyses 
Sensitivity analysis EXOGEN  Control Cost difference 
(EX vs control) 
VAT on devices and consumables £3,243 £2,557 £686 
Risk of infection annual rate of 4.9% £3,032 £2,527 £505 
Use of HRG cost of infection £3,027 £2,512 £515 
Cost of surgery (£2,350) £2,994 £2,418 £576 
Cost of surgery (£4,126) £3,058 £2,599 £459 
 
4.7 Conclusions on the economic evidence 
The economic models submitted by the sponsor are of a good general 
standard.  We found a few minor errors in coding and data entry – probably 
inherited from when the model was adapted from the published (Taylor 2009) 
evaluation of fresh fractures.  But these make little difference to the results.   
However, in adapting the published model, the sponsor made a number of 
other adjustments to modelling assumptions and parameters, some of which 
the EAC considers to be potentially misleading.  In particular, the method by 
which healing rates were extracted from the key clinical studies (Mayr and 
Schofer) and converted to monthly rates led to an overestimation of the likely 
relative effectiveness of EXOGEN compared with the control arm in the 
delayed union model.  On changing these assumptions, we found that 
EXOGEN did not appear to be cost-saving in this context. 
We found the results of the non-union model to be more robust.  Under the 
EAC preferred model, the use of EXOGEN followed by surgery only if needed 
after a further 6 months was estimated to save about £1,200 per patient 
compared with immediate surgery in patients with non-union fractures of the 
tibia.  EXOGEN remained cost-saving under a wide range of scenarios.  
There is some uncertainty over this result, due to uncertainty over two key 
drivers of the non-union cost model.  Firstly, the model is somewhat sensitive 
to changes in assumptions about the relative effectiveness of surgery 
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compared with EXOGEN, and it should be noted that the clinical evidence 
supporting the basecase assumption of equal effectiveness is of poor quality.  
Secondly, the magnitude of the cost saving with EXOGEN model depends on 
the estimated cost of surgery.   
We were initially concerned that the submitted models overestimated the 
incidence of infection (taking what appears to be a rate over approximately 
three months post surgery from the HPA, and applying it monthly) and also 
that they overestimated the cost of infections (assuming that they would all 
require an inpatient stay of one month).  However, we found that these 
assumptions actually make little difference to the results – since the absolute 
number of patients developing an infection in any of the treatment arms is 
small.  
 
Impact on the cost difference between the technology and comparator 
of additional clinical and economic analyses undertaken by the External 
Assessment Centre 
The additional analyses undertaken by the EAC did change the results as 
reported in the submission.  Early treatment with EXOGEN (at 3 months post 
fracture) did not appear to be cost saving under the EAC assumptions.   
Results were more robust for later treatment of non-union fractures (at 9 
months post fracture), and the EAC did conclude that use of EXOGEN in this 
context is likely to be cost-saving, although there is some uncertainty over this 
conclusion due to uncertainty over the relative effectiveness of surgery and 
ultrasound in this context and over the cost of surgery itself. 
 
5 Conclusions 
The clinical evidence is generally weak.  There is one large registry study 
(Mayr 2000), which provides quite robust estimates of absolute healing rates 
with EXOGEN for delayed union and non-union fractures of different long 
bones, and one randomised controlled trial comparing EXOGEN with placebo 
in a mixed population of patients with delayed and non-union fractures of the 
tibia.  Other available evidence comes from case series, which are difficult to 
summarise due to differences in the reporting of outcomes.  There is a lack of 
evidence on other outcomes of interest. 
It is clear that EXOGEN carries a much lower risk of adverse effects than 
surgery.  Surveillance data indicates that around 1.4% of patients undergoing 
surgical reduction of a long bone fracture (2.6% of patients with risk factors for 
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infection) will develop an infection, around 51% of which are serious deep 
infections (HPA 2010/11).  In contrast, reports of adverse reactions possibly 
related to the use of EXOGEN are rare. 
Delayed union 
There is no evidence – direct or indirect - comparing healing rates with 
EXOGEN and surgery in the treatment of delayed union fractures of long 
bones.  This means that it is not possible to evaluate the comparison 
requested in the scope.  However, the sponsor does present a comparison 
between early use of EXOGEN (at three months) and observation followed by 
surgery at non-union (nine months) if necessary.  This might be a clinically 
appropriate comparison if surgery would not usually be offered for delayed 
union fractures.  This comparison relies on evidence from the Schofer sham-
controlled randomised trial, and it should be noted that this study did not find a 
significant difference in healing rates, although it was not powered for this 
outcome, and it did find significant improvements in indicators of progression 
to healing (outside the scope).  It should also be noted that the Schofer trial 
included a mix of patients with fractures that would be classified as delayed 
union and non-union under the scope definition, and did not present a 
subgroup analysis.  It is therefore difficult to know to what extent the results 
apply to the specific context of delayed union.  The trial data also relates to 
tibia fractures only, so there is some uncertainty over effects for fractures of 
other long bones. 
The costing model for delayed union presented by the sponsor found a small 
cost-saving of £684 on average per patient associated with the early use of 
the EXOGEN system.  However, this result was not robust to sensitivity 
analysis conducted by the EAC.  We found that different (legitimate) methods 
of estimating healing rates from the available clinical data reversed the 
conclusions.  Under our best estimate, early use of EXOGEN for delayed 
union was around £500 more expensive than waiting for surgery at non-union. 
Non union 
There is no direct comparative evidence for outcomes of interest for EXOGEN 
versus surgery in non-union fractures of long bones.  There is a fair estimate 
of the absolute healing rate with EXOGEN from a large registry study, and 
supportive evidence from other smaller non-comparative case series.  There 
are also estimates of the healing rate with surgery from case series.  Although 
these non-controlled studies provide reasonable evidence of effectiveness for 
each intervention, it is difficult to gauge the size of their relative effect.  
For the non-union costing model, the sponsor assumes equal healing rates 
with EXOGEN and surgery.  Together, this assumption and the sponsor’s 
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estimate of the cost of surgery yield a cost-saving for EXOGEN of about 
£2310.  This is a much larger difference than in the delayed union model, 
which is not surprising given that the proposed pathway for non-union 
assumes that EXOGEN will directly displace the need for further surgery.  The 
EAC best estimate of the cost-saving with EXOGEN versus surgery in non-
union is lower than that of the sponsor: £1,164 cost saving on average per 
patient.  This makes the results of the non-union model somewhat susceptible 
to uncertainty over the relative effectiveness and costs of EXOGEN and 
surgery. 
 
6 Implications for research 
Comparative evidence for the relative clinical and cost effectiveness of 
EXOGEN and surgery for the treatment of non-union long bone fractures is 
lacking.  This could be provided by a randomised trial, or if this is not feasible 
in the non-union population comparative observational data could be of used. 
Corroboration of the results of the Schofer trial, with further randomised 
studies of the clinical and cost-effectiveness of early use of EXOGEN in 
delayed union would also be valuable.  Evidence for long bones other than 
the tibia would help to establish generalisability.
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Appendix A: Clinical study methods 
The below are sponsor’s summary of methodology for individual studies and the EAC’s comments in the last right column. The 
sponsor’s submission are in grey and the EAC’s comments in black.   
 
Study name      Schofer  2010 Improved healing response in delayed unions of the tibia with low-intensity 
pulsed ultrasound: results of a randomized sham-controlled trial  
Comments by the EAC 
Objectives Test the hypothesis that in comparison to a 
placebo, 16 consecutive weeks of LIPUS treatment would accelerate the 
progression to healing as evidenced by quantitative radiographic 
measurements of bone mineral density (BMD) and the reduction in the size of 
the residual gap area. 
Agree 
Location  Six centres in Germany Agree 
Design   Multicentre randomized sham-controlled trial Agree 
Duration of study  16 weeks Agree 
Sample size  101 Agree 
Inclusion criteria  All adult patients who had sustained a tibial shaft fracture that subsequently 
showed inadequate progress toward healing (i.e., delayed union) and 
provided informed consent. 
Agree 
Exclusion criteria Patients who were pregnant had a revision or reoperation at the fracture site 
within 16 weeks of enrollment, had a deep wound infection, or had excessive 
malalignment. 
Agree 
Method of randomisation  Treatment was assigned randomly to each subject on a 1:1 basis in blocks of 
six and randomization was stratified within each clinical site. The 
randomization code was developed using a computer random number 
generator. The investigators, subjects and sponsor were blinded to the 
random allocation sequence prior to initiation of treatment and throughout 
the entire duration of this study. 
Agree 
Method of blinding  A sham device was used. Agree 
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Intervention(s) (n =51 ) and 
comparator(s) (n =50 ) 
n=51 (EXOGEN group) 
n=50 (sham group) 
Agree 
Baseline differences Age, female, fracture age, distribution of fracture age, open fracture, surgical 
treatment, smoking status. 
Agree 
Duration of follow-up, lost to 
follow-up information 
 16 weeks Agree 
Statistical tests For each of five stochastically completed data sets, analysis of covariance 
(ANCOVA) was used to estimate a treatment group contrast that controlled 
for the baseline value of the clinical endpoint as well as clinical site.  
Subject baseline characteristics were summarized using frequency and 
percentage distributions or descriptive statistics, as appropriate. Proportions 
were compared using the Chi-square test with Yates’ continuity correction or 
Fisher’s exact test. Continuous variables were compared using the two sample 
t-test. 
Agree 
Primary outcomes (including 
scoring methods and timings of 
assessments) 
Change in BMD between pre-treatment and 16 weeks: 
Results from the descriptive ‘completers’ analysis of observed cases are 
expressed on the log scale in order to allow comparison of ES between BMD 
and gap area. The mean (SD) changes from pre-treatment to 16 weeks follow-
up in log BMD were 0.87 (0.67) HU and 0.57 (0.38) HU for active- and sham-
treated groups, respectively (t-test, p = 0.014) (Figure 1). The difference in 
these means, divided by the pooled standard deviation results in a 
standardized ES of 0.53 (95% CI 0.09 to 0.97). The corresponding mean 
changes (SD) in log gap area were -0.131 (0.072) mm2 and -0.097 (0.070) 
mm2 for active and sham groups, respectively (p = 0.034) resulting in a 
standardized effect size of comparable absolute value (ES = -0.47, 95% CI -0.91 
to -0.03). 
Agree 
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Secondary outcomes (including 
scoring methods and timings of 
assessments) 
Change in gap area at the fracture site:                         A statistically significant 
benefit of LIPUS treatment was realized in terms of mean reduction in bone 
gap area based on log transformed data using multiple imputation methods 
(1-sided, p = 0.014). The exponentiated difference in log mean changes was 
0.974 (90% CI 0.956 to 0.993) reflecting proportionally smaller average gap 
area. For untransformed data, the group difference in mean adjusted changes 
from baseline in bone gap area was -0.457 mm2 (90% CI -0.864 to -0.049) with 
1-sided p = 0.03 similarly reflecting a smaller expected gap area in LIPUS-
treated subjects compared to controls. 
Plus, healing rates were 65% (33/51) 
for EXOGEN, 46% (23/50) for 
placebo in 16 weeks follow-up. . 
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Study name  
Rutten 2008 
Low-intensity pulsed ultrasound increases bone volume, osteoid thickness 
and mineral apposition rate in the area of fracture healing in patients with a 
delayed union of the osteotomized fibula  
Comments by the EAC 
Objectives Investigate how LIPUS affects bone healing at the tissue level in patients with 
a delayed union of the osteotomized fibula, by using histology and 
histomorphometric analysis to determine bone formation and bone 
resorption parameters  
Agree 
Location  Single centre in the Netherlands  Agree 
Design   Randomised, double-blind, placebo controlled Agree 
Duration of study  4 months Agree 
Sample size  13 patients Agree 
Inclusion criteria   Patients with fibular delayed union 6 months post- High tibial osteotomy 
(HTO) 
 
Exclusion criteria  Patients with union of the fibula post - HTO Not mentioned in the paper 
Method of randomisation   Computerised randomisation Agree 
Method of blinding   A sham device was used Agree 
Intervention(s) (n = ) and 
comparator(s) (n = ) 
 EXOGEN = 7 
Placebo = 6 
Agree 
Baseline differences None reported The paper reported age, gender, 
smoking status, fracture age and 
delayed union type of the two 
treatment group but no statistical 
test was reported, probably due to 
the small sample size.  
Duration of follow-up, lost to 
follow-up information 
 2- 4 months – no loss to follow-up Agree 
Statistical tests  Statistical analysis of the data was performed using a Student's independent 
t-test (two-tail). The values of the histomorphometric parameters are 
expressed as mean ± SEM. A p-value of b 0.05 is considered significant. 
Agree but due to the small sample 
size these test did not make much 
sense.  
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Primary outcomes (including 
scoring methods and timings of 
assessments) 
 1) area of new bone formation, 2) area of cancellous bone, and 3) area of 
cortical bone.  
Agree 
Therefore this study did not include 
any outcome measures in the scope.  
Secondary outcomes (including 
scoring methods and timings of 
assessments) 
 None  Agree 
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Summary of methodology for randomised controlled trials - SURGERY  
Study name 
Cacchio 2009 
Extracorporeal Shock-Wave Therapy Compared with Surgery for Hypertrophic 
Long-Bone Non-unions 
Comments by the EAC 
Objective Compare the results of extracorporeal shock-wave therapy produced by two 
different devices with those of surgical treatment in the management of long-
bone non-union. 
Agree 
Location Multicentre in Italy Agree 
Design  Randomised, double-blind, controlled Agree 
Duration of study 6 months Agree 
Patient population 156 Agree 
Sample size 126 Agree 
Inclusion criteria long-bone non-union and 
skeletal maturity. 
Agree 
Exclusion criteria bone tumours, pathologic fractures, infected non-unions, breakage of fixation 
devices, an implanted pacemaker, blood coagulation disorders, use of 
anticoagulant drugs, and pregnancy. 
Agree 
Intervention(s) (n = ) and 
comparator(s) (n = )  
SWT (1)= 42, SWT (2) = 42 
Surgery = 42 
Agree 
Baseline differences None reported No significant differences were 
found between study groups, in 
terms of age, gender, duration of 
non-union, type of non-union, pain 
score, DASH score and LEFS score.  
How were participants followed-
up (for example, through pro-
active follow-up or passively). 
Duration of follow-up, 
participants lost to follow-up  
Active follow up over 24 months 
15 patients were lost to follow up 
Agree 
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Statistical tests To test the primary end point, a two-sided chi-square test was carried out to 
compare the success rate at six months in the extracorporeal shock-wave 
therapy groups with that in the surgery group; the level of significance was 
5%. 
To test the secondary end points, a two-way analysis of variance, with the 
group as the between-subjects factor and time as the within-subjects factor, 
was used to assess whether there were significant differences in the DASH, 
LEFS, and visual analogue scale scores among the three groups and between 
the preoperative and scheduled follow-up time points within each group. 
 A Tukey post hoc comparison was used to assess significant differences 
between mean values when a significant main effect and interaction were 
found. The model for all of the analyses included the main effects of 
treatment, time, and the treatment · time interaction. Significance levels for 
multiple comparisons were adjusted with the Bonferroni procedure. The level 
of significance was set at p < 0.05. 
Agree 
Primary outcomes (including 
scoring methods and timings of 
assessments) 
Radiographic healing - callus bridged the 
non-union site on all four cortices 
Agree. Radiographic test of healing 
was assessed at 6 months.  
Secondary outcomes (including 
scoring methods and timings of 
assessments) 
Clinical results – The DASH questionnaire for the patients with an upper-limb 
non-union and the LEFS questionnaire for the patients with a lower-limb non-
union. 
Agree 
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Study name 
Friedlaender 2001 
Osteogenic Protein-1 (Bone Morphogenetic Protein-7) in the Treatment of 
Tibial Non-unions: A Prospective, Randomized Clinical Trial Comparing rhOP-
1 with Fresh Bone Autograft* 
Comments by the EAC 
Objective Comparison the clinical and radiographic results with this osteogenic molecule 
and those achieved with fresh autogenous bone. 
Agree 
Location Multicentre USA Agree 
Design  controlled, prospective, randomized, partially blinded, Agree 
Duration of study 24 months, primary endpoint 9 months Agree 
Patient population Adults with non-unions Adults with tibial non-unions 
Sample size 124 fractures 122 patients (2 patients had two 
non-union fractures) 
Inclusion criteria Each patient had a tibial non-union, as based on a 1988 FDA guidance 
document definition requiring 9 months duration of the non-united fracture 
with no evidence of progressive healing over the previous 3 months 
Agree 
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Exclusion criteria Patients who, in the judgment of their treating orthopaedic surgeon, were 
candidates for internal fixation alone (generally reaming and an 
intramedullary rod), were excluded, as were patients with clinically apparent 
infection at the fracture site. 
1. Patients who do not meet the study inclusion criteria. 2. Patients who are 
skeletally immature.   3. Patients unable or unwilling to fulfil the follow-up 
requirements. 4. Patients with severely compromised soft-tissue coverage at 
the non-union site, sufficient to impair bone healing. 5. Patients with non-
unions resulting from pathological fractures (neoplasia, metabolic bone 
disease). 6. Patients receiving radiation, chemotherapy, immunosuppression, 
or chronic steroids. 7. Patients who are or could become pregnant during the 
study or who are breastfeeding. 8. Patients with active infection systemically 
or at the site of non-union. 9. Patients receiving other investigational 
treatment. 10. Patients with congenital or synovial pseudarthrosis of the tibia. 
11. Patients with complete neuropathy that would interfere with walking or 
appreciation of pain. 12. Patients with non-unions of multiple bones (other 
than the tibia). 13. Patients with a known autoimmune disease. 14. Patients 
with known sensitivity to collagen. 
Agree  
Intervention(s) (n = ) and 
comparator(s) (n = )  
Surgery plus rhOP-1 = 63 fractures 
Surgery plus autograft = 61 fractures 
Agree but note that both treatments 
involved surgical interventions using 
different material.  
Baseline differences These two randomly assigned populations were similar in most respects, 
including age, sex ratio, duration of non-union, and the number of prior 
surgical interventions. There was, however, a statistically higher prevalence of 
atrophic non-unions (41 compared with 25%, p = 0.048) and a strong trend 
toward more smokers (74 compared with 57%, p = 0.057) in the OP-1 group. 
Agree 
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How were participants followed-
up (for example, through pro-
active follow-up or passively). 
Duration of follow-up, 
participants lost to follow-up  
These criteria were evaluated at 1, 2, 3, 6, 9, 12, and 24 months following 
surgery, and the primary end-point of the study was the 9-month visit. 
 
No loss to follow-up 
Agree 
Statistical tests  Analyses of efficacy outcomes were conducted with use of a chi-square test, 
and a p value of ≤ 0.05 was considered statistically different. Differences in 
the frequency of adverse events were evaluated by a two-tailed chi-square or 
Fisher's exact test, as appropriate. Comparison of the means of operative 
blood loss was performed with a Student t test. For the length of stay and 
operative time, Wilcoxon rank sum tests were performed, which are 
appropriate for variables that are not normally distributed. A p value of ≤ 0.05 
for analysis of safety variable was considered significant. 
Agree 
Primary outcomes (including 
scoring methods and timings of 
assessments) 
Assessment criteria included the severity of pain at the fracture site, the 
ability to walk with full weight-bearing, the need for surgical re-treatment of 
the 
non-union during the course of this study, plain radiographic evaluation of 
healing, and physician 
satisfaction with the clinical course. 
Healing had two definitions in this 
study, one is radiographic evidence 
of bone bridging on at least one 
view, and the other was bridging in 
at least three of four views. The 
second definition was consistent 
with the scope. Also, the fully 
weight-bearing criteria was under 
the condition of ‘less than severe 
pain’ which was different from 
painless weight bearing as defined in 
the scope.   
Secondary outcomes (including 
scoring methods and timings of 
assessments) 
Not stated which is primary and which secondary  
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Summary of methodology, observational studies - EXOGEN 
Study name 
Gebauer 2005 
Low-Intensity Pulsed Ultrasound: Effects on Non-unions Comments by the EAC  
Objective To study the efficacy of EXOGEN low-intensity pulsed ultrasound on non-
union cases with a minimum fracture age of 8 months. 
Agree 
Location Germany and Austria Agree 
Design  Self-paired control study where the control is the patient’s own history of 
failed treatments.  
The self-paired study assumed a 5% 
healing rate for non-union patients 
without any interventions.   
Duration of study  22 months 168 days of EXOGEN treatment 
duration. 402 days long term 
telephone follow-up.  
Patient population Consecutively entered German and Austrian population of fractures, of all 
fracture ages, who were prescribed the use of EXOGEN as an alternative to 
surgery, based on the patient’s decision. All the non-union fractures were 
consecutively entered into the study, provided the patient did not decide on a 
surgical revision of the non-union. 
Agree  
Sample size 85 treated non-union cases. 67 cases met the study inclusion criteria Agree 
Inclusion criteria  Established non-union defined as a fracture with a minimum age of 8 
months from the fracture date 
 Radiographic assessments displaying a clearly visible fracture line, 
before and at the start of EXOGEN treatment indicating that the 
fracture healing process had not progressed or had stopped for at 
least 3 months before the start of EXOGEN treatment 
 A minimum period of 4 months without surgical intervention before 
EXOGEN. 
Agree 
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Exclusion criteria  Patients who were not skeletally mature 
 Women who were pregnant or nursing 
 Patients who could not comply with their physicians’ instructions 
 Fractures that were malaligned, grossly unstable, actively infected or 
had extensive bone loss 
Agree 
Intervention(s) (n = ) and 
comparator(s) (n = )  
EXOGEN (n=67) 
Non-union (n=67) 
The comparator non-union group 
was the patients themselves as self-
pair.  
Baseline differences   This is not relevant as the patients 
were self-paired.  
How were participants followed-
up (for example, through pro-
active follow-up or passively). 
Duration of follow-up, 
participants lost to follow-up  
Anterior / posterior and lateral radiographs were taken at 1-2 month intervals 
after the start of EXOGEN. Clinical examination occurred at each follow-up 
visit. Long term follow up conducted by telephone an average of 402 days 
after trial completion. Five patients were lost to long term follow-up of the 57 
healed patients. 
Agree 
Statistical tests One-sided test used to calculate the p-value to assess the superiority of 
treatment with the EXOGEN device for the per cent of non-unions healed 
Fisher’s exact test used to contrast strata of patient and fracture 
characteristics 
This test is not relevant here as the 
comparator was the patients 
themselves.  
Primary outcomes (including 
scoring methods and timings of 
assessments) 
Healed non-union when the fracture was both clinically and radiographically 
healed. 
Clinical healing was defined as no pain or motion upon gentle stress, and 
weight bearing if applicable. 
Radiographic healing defined as three of four bridged cortices for long bones 
and bridging callus for flat bones.  
Agree 
Secondary outcomes (including 
scoring methods and timings of 
assessments) 
  None 
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Study name  
Jingushi 2007 
Postoperative delayed union or non-union long bone fractures Comments by the EAC 
Objective Evaluate the impact of EXOGEN on the above Agree 
Location Multiple centres in Japan Agree 
Design  Prospective, multi-centre, case series Agree 
Duration of study Treated until healed (2-7 months)  Not clear in the paper 
Patient population All patients long bone delayed union or non-union following operative 
treatment 
Agree 
Sample size 72 fractures 40 non-union and 32 delayed unions 
Inclusion criteria Delayed union or non-union fractures of humerus, radius, ulna, femur or tibia 
following operative treatment. Closed or open (Gustilo grades 1 to III B) 
Agree 
Exclusion criteria Fractures not meeting the above inclusion criteria Agree 
Intervention(s) (n = ) and 
comparator(s) (n = )  
EXOGEN (n=72) Agree 
Baseline differences Not applicable  Mean age 40 yrs. Mean age 40.4. 
Mean fracture age 18.9 month (3-
159) 
How were participants followed-
up (for example, through pro-
active follow-up or passively). 
Duration of follow-up, 
participants lost to follow-up  
Clinical and radiographic evaluation by experienced orthopaedic surgeons on 
a monthly basis until healed. 
Agree 
Statistical tests Not applicable for primary endpoint but statistical analysis for baseline 
characteristics on union rate  
Agree 
Primary outcomes (including 
scoring methods and timings of 
assessments) 
Clinical and radiographic healing as determined by experienced orthopaedic 
surgeons 
Healing rate and average healing 
time 
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Secondary outcomes (including 
scoring methods and timings of 
assessments) 
 Assessment of impact of background factors on healing rates. Include the time from the most 
recent operation to the beginning of 
EXOGEN treatment.  
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Study name  
Lerner 2004 
Compound High Energy Limb Fractures with Delayed Union  EAC comments 
Objective Evaluate the impact of EXOGEN on the above Agree 
Location Ramban Medical Center and Faculty of Medicine, Technion, Israel Agree 
Design  Prospective, single centre, case series Agree 
Duration of study Treated until healed (14 to 52 wks)  EXOGEN was used until the fracture 
healed with mean duration of 26 
weeks (13-52) 
Patient population High energy fractures (war injuries, road traffic and work accidents). All 
Gustilo open fractures (grades II to III C) 
Agree 
Sample size 17 patients, 18 fractures 16 patients completed the EXOGEN 
treatment process 
Inclusion criteria Delayed bone healing (18 to 172 weeks) or impaired bone healing (2 fractures 
at 4 weeks). 
No radiographic evidence of racture 
callus appearance was noted 4 - 38 
(median 6) months after prolonged 
fixation time. 
Exclusion criteria Low energy fractures Not mentioned in the paper 
Intervention(s) (n = ) and 
comparator(s) (n = )  
EXOGEN (n=18) 16 patients were long bone delayed 
unions 
Baseline differences Not applicable  Age ranged from 19 - 48 yrs. 
How were participants followed-
up (for example, through pro-
active follow-up or passively). 
Duration of follow-up, 
participants lost to follow-up  
Usual and customary follow up until healed, and long term follow up out to 6 
years. 
1 patient lost to follow up 
Agree 
Statistical tests Not applicable Agree.  
Primary outcomes (including 
scoring methods and timings of 
assessments) 
Fracture healing as determined by experienced orthopaedic surgeon Healing time  
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Secondary outcomes (including 
scoring methods and timings of 
assessments) 
 Not applicable Healing rate 
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Study name 
Mayr 2000 
Ultrasound – an alternative healing method for non-unions? EAC comments 
Objective A report on patients suffering from healing problems who use EXOGEN 
therapy for treatment of delayed or non-unions. 
Agree 
Location Augsburg Hospital, Augsburg, Germany SAFHS worldwide prescription 
registry for delayed union and non-
union patients with a subgroup from 
the local clinic. 
Design  Full  prospective patient registry population compared with Ausberg’s well 
controlled trial  
Reported SAFHS registry and 
Ausgerg clinic as whole sample and 
subgroup and compared between 
the two.  
Duration of study  From October 17,1994, to July 14, 1997, Agree 
Patient population 1,317 patients total; 42 patients-Ausberg Delayed union and non-union 
patients treated with EXOGEN.  
Sample size 1,317 951 delayed unions and 366 non-
unions from SAFHS, 42 from 
Ausberg.  
Inclusion criteria Non-union (9 months post fracture) or delayed union (3-9 months post 
fracture)  
Agree 
Exclusion criteria  Not reported Agree.  
Intervention(s) (n =) and 
comparator(s) (n =)  
Augsburg patients – (n=42) 
Full registry cohort – (n=1,317) 
The non-union becomes a perfect example of biological self-pairing since the 
patient has not healed, and subsequent treatment intervention results in a 
healing status change. This healed status change is the basis for effectiveness 
since the patient serves as his or her own control. 
The intervention was EXOGEN. There 
was no comparators in this study but 
a whole sample and subgroup 
comparison. It is not clear how the 
self-pair analysis relevant here.  
Baseline differences  N/A Not reported.  
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How were participants followed-
up (for example, through pro-
active follow-up or passively). 
Duration of follow-up, 
participants lost to follow-up  
Only completers were included in the analysis therefore there are no reported 
losses to follow-up. 
Agree. 
Statistical tests  Not stated Statistical tests were used to 
examine the difference between the 
SAFHS registry patients and local 
clinic patients in terms of healing 
rate and average healing time, in 
delayed union and non-union 
patients.  
Primary outcomes (including 
scoring methods and timings of 
assessments) 
 
Bony healing, defined as follows:  healing criteria: three cortices bridged in 
two X-ray planes or trabecular bridging of at least 80% of the fracture in the 
case of cancellous fractures  
Agree.  
Secondary outcomes (including 
scoring methods and timings of 
assessments) 
 None stated Agree.  
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Study name  
Nolte - 2001 
Low-Intensity Pulsed Ultrasound in the Treatment of Non-unions  EAC comments 
Objective To evaluate the effect of EXOGEN low intensity pulsed ultrasound for the 
treatment of established non-unions in a consecutively enrolled patient 
population to see if ultrasound had an effect in the treatment of non-union. 
Agree 
Location The Netherlands Agree 
Design  Self-paired study where each patient served as their own control, with the 
prior failed treatments being the basis for evaluating EXOGEN. Each patient 
was diagnosed with a non-union, with no expectation of healing. EXOGEN was 
the only change in the treatment regimen – no additional treatment 
procedure was allowed at the start of or during the period of EXOGEN low 
intensity pulsed ultrasound treatment to influence the effect of the 
ultrasound therapy. 
This was a case series non-union 
study. The way to use non-union 
patients as their own comparators 
may be of clinical meaning but the 
statistical analysis did not provide 
meaningful information for the 
decision problem.  
Duration of study 18 months It was not clear but the paper 
mentioned that 1 year after EXOGEN 
treatment, the patients were 
interviewed by telephone. Seem that 
the patients were followed until 
fracture healed (maximum 398 days) 
Patient population Patients presented in trauma departments Agree 
Sample size 29 fractures reported 
21 long bone fractures (tibia, femur, fibula, humerus, ulna, radius) 
22 long bone fractures 
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Inclusion criteria Patients with a non-union fracture as defined by: 
 A failure of the fracture to unite at a minimum of 6 months from the time 
of fracture 
 Radiographic healing had not progressed or had stopped for a minimum 
period of 3 months before the start of EXOGEN treatment 
 The fracture line was clearly visible in two orthogonal views 
 The interval between the last operative procedure and the start of 
EXOGEN treatment was a minimum of 90 days 
Agree 
Exclusion criteria  Not reported Agree 
Intervention(s) (n = ) and 
comparator(s) (n = )  
 EXOGEN (n=21) 
Non-union (n=21) 
Non-union long bone fractures =  22 
Baseline differences   Average age 47 yrs (range 18 - 90). 
Average  frature age 61 weeks 
(range 25 - 137 weeks). 
How were participants followed-
up (for example, through pro-
active follow-up or passively). 
Duration of follow-up, 
participants lost to follow-up  
Patients were actively examined in the outpatient department of their 
respective hospitals at regular intervals of 6 to 8 weeks. 
No patients were lost to follow-up. Three patients withdrew themselves from 
the study. 
Agree 
Statistical tests Kruskal-Wallis test was used for contrasting heal time and fracture age. The 
Kruskal-Wallis analysis was a two sided 99% confidence level Monte Carlo 
estimate of the exact p value computed.  
Fisher’s exact test was used for heal rates. 
This was the statistical test for self-
paired non-union patients assuming 
5% healing rate without any 
treatments.  
Primary outcomes (including 
scoring methods and timings of 
assessments) 
Clinical healing on the non-union fracture as defined by: 
 Absence of pain 
 Weight bearing without pain or normal function of the limb 
Radiographically healed non-union fracture as defined by: 
 Three or four cortices bridged 
Agree 
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Secondary outcomes (including 
scoring methods and timings of 
assessments) 
 None  
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Study name     Romano 1999 Low-Intensity, Pulsed Ultrasound for the Treatment of Septic 
Pseudoarthrosis  
EAC comments 
Objective To describe the clinical effects of low intensity pulsed ultrasound for the 
treatment of septic non-unions. 
Agree 
Location Istituto Ortopedico Gaetano Pini,  
Milan, Italy 
Agree 
Design  Case Report Agree 
Duration of study Treated until healed (95 to 181 days) Treated until consolidation was 
achieved 
Patient population Patients with septic pseudoarthrosis and delayed consolidation Agree but the delayed consolidation 
may not be consistent with delayed 
union in the scope.  
Sample size 15 fractures 
13 long  bones (tibia, humerus femur) 
Agree 
Inclusion criteria Patients with septic pseudoarthrosis and delayed consolidation and: 
 Sufficiently stable fracture 
 An infection controlled with antibiotics 
 Sufficient vascularization 
 Skin covering 
Agree 
Exclusion criteria  Not reported Agree 
Intervention(s) (n = ) and 
comparator(s) (n = )  
EXOGEN (n=15) 
NA 
Agree 
Baseline differences NA Age ranged from 28 - 78 yrs. 
Fracture age ranged from 8 - 30 
months. 
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How were participants followed-
up (for example, through pro-
active follow-up or passively). 
Duration of follow-up, 
participants lost to follow-up  
Patient follow-up information not provided 
No patients were lost to follow-up.  
Agree 
Statistical tests  NA 
 
Agree 
Primary outcomes (including 
scoring methods and timings of 
assessments) 
Consolidation (specific definition not provided) This outcome measure is not 
included in the scope. 
Secondary outcomes   None Agree 
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Summary of methodology, observational studies - SURGERY 
Study name 
Bellabarba 2002 
Indirect reduction and plating of distal femoral non-unions EAC comments 
Objective To observe and report the clinical results of indirect reduction and plating in 
the treatment of distal femoral non-unions 
Agree 
Location Single centre,  USA Agree 
Design  Prospective consecutive study Agree 
Duration of study  Average follow up 23 months Agree 
Patient population A consecutive series of patients with non-union of the distal femur, nineteen 
of whom had undergone operative initial fracture care 
Note that the definition of non-
union (6 months no progress of 
healing) was different from the 
scope 
Sample size  20 Agree 
Inclusion criteria Distal femoral non-unions Agree 
Exclusion criteria  Not stated Agree 
Intervention(s) (n = ) and 
comparator(s) (n = )  
 20 surgical plating Agree 
Baseline differences  N/A Mean age 48 yrs (ranged 18 - 92). 
Interval from injury  to non-union 10 
months (ranged 3 - 25) 
How were participants followed-
up (for example, through pro-
active follow-up or passively). 
Duration of follow-up, 
participants lost to follow-up  
Follow up method not stated 
No loss to follow up 
Agree 
Statistical tests Not stated None  
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Primary outcomes (including 
scoring methods and timings of 
assessments) 
Healing rate and time, (Clinical and radiographical) operative blood loss and 
time, incidence of complications including instrumentation failure, loss of 
fixation, infection, and postoperative malalignment. Both the Böstman and 
Hospital for Special Surgery knee scores were used to quantify postoperative 
clinical results at an average follow-up of twenty-three months (range 12 to 
60 months). 
Agree 
Secondary outcomes  Not stated Agree 
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Study name 
Birjandinejad 2009 
Augmentation plate fixation for the treatment of femoral and tibial non- 
unions after intramedullary nailing. 
EAC comments 
Objective Present authors’ experience in plating as an augmentation to primary nailing  Agree 
Location Single centre, Iran Agree 
Design   Prospective case series Agree 
Duration of study 1 year minimum follow up  Agree 
Patient population Femoral and tibial non-unions Agree 
Sample size  25 Agree 
Inclusion criteria Not stated Agree 
Exclusion criteria  Infection Agree 
Intervention(s) (n = ) and 
comparator(s) (n = )  
 25 surgical intervention Agree 
Baseline differences  N/A Mean age 31.4 yrs (ranged 18 - 53). 
How were participants followed-
up (for example, through pro-
active follow-up or passively). 
Duration of follow-up, 
participants lost to follow-up  
Clinic attendance Agree 
Statistical tests  Not stated Agree 
Primary outcomes (including 
scoring methods and timings of 
assessments) 
Clinical and radiographical healing. Disappearance of lucencies on X-ray and 
ability to weight bear 
No information of ability to weight 
bearing.  
Secondary outcomes (including 
scoring methods and timings of 
assessments) 
 Not stated Agree 
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Study name 
Khalil 2010 
Contoured plating for proximal ulna non-union: an improved technique EAC comments 
Objective Present results of an improved plating technique Agree 
Location Single centre, Faculty of medicine, Tanta University, Egypt Agree 
Design   Prospective case series Agree 
Duration of study  22 months average follow up  Agree 
Patient population Patients with proximal ulna non-union Agree but no clear definition 
of non-union was reported 
Sample size  21 Agree 
Inclusion criteria Ununited proximal ulnar fractures Agree 
Exclusion criteria Cases with painless stiff non-union with a stable elbow having a range of movement 
greater than 90° were excluded 
Agree 
Intervention(s) (n = ) and 
comparator(s) (n = )  
 21 surgical plating Agree 
Baseline differences  N /A Mean age 41.7 yrs. 
How were participants followed-
up (for example, through pro-
active follow-up or passively). 
Duration of follow-up, 
participants lost to follow-up  
Every 2 weeks Agree 
Statistical tests  Not stated Agree 
Primary outcomes (including 
scoring methods and timings of 
assessments) 
 Clinical and radiographic healing was assessed every 2 weeks 
Functional outcomes were calculated using the Broberg-Morrey scoring system.  
Radiographs were evaluated for union, articular congruity and alignment. 
Radiographic signs of arthritis were graded according to the system of Broberg and 
Morrey 
Agree 
Secondary outcomes (including 
scoring methods and timings of 
assessments) 
 None stated Agree 
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Study name 
Lin 2010 
Allografting in Locked Nailing and Interfragmentary Wiring for Humeral Non-
unions 
EAC comments 
Objective Compare outcomes after repair of humeral non-unions when morsellized fresh-
frozen allograft or autograft was used to augment repair by intramedullary nailing 
Agree 
Location Single centre, Taiwan Agree 
Design   Prospective, non-blinded, comparative study Agree 
Duration of study + 2 years Agree 
Patient population Patients with humeral non-union Agree but definition of non-
union was different from the 
scope (6 months no progress)  
Sample size  65 Agree 
Inclusion criteria Humeral shaft (3 cm below the lesser tuberosity and 5 cm above the olecranon 
fossa) non-union of more than 6 months’ duration with gross instability at the non-
union site 
Agree 
Exclusion criteria  Exclusion criteria were non-unions with intra-articular extension, active deep 
infection, or bone defect greater than 3 cm 
Agree 
Intervention(s) (n = ) and 
comparator(s) (n = )  
Surgery plus allograft = 36 
Surgery plus autograft = 28 
Agree 
Baseline differences  No significant differences Agree 
How were participants followed-
up (for example, through pro-
active follow-up or passively). 
Duration of follow-up, 
participants lost to follow-up  
Follow up though regular clinic attendance. The follow up was defined as the 
duration between the operation and the last regular follow up before the article was 
written. 
Agree 
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Statistical tests Statistical analysis was performed using SPSS software, Version 16 (SPSS Inc, 
Chicago, IL). Continuous variables were compared with Student’s t tests. Binary 
variables were compared with chi square tests (comparing two proportions) or 
Fisher’s exact tests if cell counts were less than five. For power analysis, with a usual 
level of statistical significance (α = 0.05 for a two-sided test) and a given power of 
0.8 (β = 0.2), the present sample size could detect a minimal difference of 3.0 weeks 
for time to union and 4.8 points for Neer score. 
Since both treatments were 
surgical process, the statistical 
analyses don’t provide extra 
information to address the 
decision question.  
Primary outcomes (including 
scoring methods and timings of 
assessments) 
Primary end points were union rate and functional recovery. The follow up was 
defined as the duration between the operation and the last regular follow up before 
this article was written. Clinical union was defined as visible callus bridging the 
fracture in at least three cortices on radiographs and the patients could use their 
arms without considerable pain or weakness. Although this was an open-label study, 
the investigators had no special preference regarding the graft type. The end points 
were measured by two blinded, fellowship-trained orthopaedic trauma surgeons 
(SMH, XYH). The two evaluators had pre-study consensus on examination methods. 
Functional assessment included Neer functional score] and Constant and Murley 
score for shoulders, Mayo performance score for elbows, and shortened Disabilities 
of the Arm, Shoulder, and Hand (QuickDASH) score for the upper extremity function. 
Postoperatively, the Constant and Murley score was compared between the injured 
and uninjured arms 
Agree 
Secondary outcomes (including 
scoring methods and timings of 
assessments) 
Secondary end points included operative blood loss, operation time, hospital stay, 
time to fracture healing, and complications. 
Agree 
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Study name 
Livani 2010 
Anterior plating as a surgical alternative in the treatment 
of humeral shaft non-union 
EAC comments 
Objective Report the results of anterior plating procedure Agree 
Location Single centre, Brazil Agree 
Design   Prospective case series Agree 
Duration of study  36 months Agree 
Patient population Patients with humeral non-union Agree but non-union was defined as no clinical, 
radioological or bone scan signs of healing after 8 months 
Sample size  15 Agree 
Inclusion criteria Not stated Patients with humeral shaft fracture who had no clinical, 
radioological or bone scan signs of healing after 8 months 
Exclusion criteria  Not stated Agree 
Intervention(s) (n = ) and 
comparator(s) (n = )  
 15 treated with anterior plate Agree 
Baseline differences  N/A Mean age 37.53 yrs (range 18 - 74). 
How were participants followed-
up (for example, through pro-
active follow-up or passively). 
Duration of follow-up, 
participants lost to follow-up  
Clinic attendance Agree 
Statistical tests  No loss to follow up None 
Primary outcomes (including 
scoring methods and timings of 
assessments) 
 Clinical ( method not stated)and radiographic healing 
callus formation and cortical continuity) 
 
Callus formation and cortical continuity as evidence of 
radiological union. Clinical assessment included 
functional outcomes for patients who returned to work 
with no limitation on daily activities.  
Secondary outcomes (including 
scoring methods and timings of 
assessments) 
 Not stated Agree 
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Study name 
Razaq 2010 
EXCHANGE NAILING FOR NON-UNION OF FEMORAL SHAFT FRACTURES EAC comment 
Objective Analyse the role of exchange nailing for aseptic non-union of femoral shaft fractures. Agree 
Location Single centre, Pakistan Agree 
Design   Prospective, consecutive case series Agree 
Duration of study  18 months Not clear in the paper 
Patient population Patients with aseptic femoral non-unions Agree 
Sample size  41 patients, 43 fractures Agree 
Inclusion criteria Inclusion criteria 
1. All male and female patients who were aged 13 years and above 
2. All patients who had initially closed post traumatic fractures of the shaft femur 
3. All patients who had one or more times previous 
surgical treatment done for the fracture 
4. All patients had last surgery for the fracture in the preceding 9–12 months in the form of 
IM nailing. (either K-nail or interlocking nail) 
5.All patients had aseptic hypertrophic or atrophic non-union on clinical and radiological 
assessment 
performed at 9 months or later after the last surgery 
6. All patients had less than 1cm shortening and no bone comminution or bone loss at the 
time of study 
Agree 
Exclusion criteria  1. Patients with infected non-unions 
2. Patients who had segmental bone defects greater than one cm 
3. Patients with bent or broken IM nail/Interlocking nail which had required open removal. 
Agree 
Intervention(s) (n = ) and 
comparator(s) (n = )  
 Exchange nailing = 43 Agree 
Baseline differences  N/A  Mean age 38.8 yrs (SD 
13.8) 
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How were participants followed-
up (for example, through pro-
active follow-up or passively). 
Duration of follow-up, 
participants lost to follow-up  
All operated patients were followed-up in the outpatient department at 2 weeks for suture 
removal and wounds examination. Patients were followed up subsequently for clinical 
and/or radiological check-up at one month intervals for minimum period of one year after 
the surgery or till time when bone healing at non-union site has occurred. The fracture 
showing radiological 
evidence of healing, as confirmed by independent radiologist, was considered healed. 
Agree 
Statistical tests  Not stated Agree 
Primary outcomes (including 
scoring methods and timings of 
assessments) 
 Radiographic healing (exact method not stated) Agree 
Secondary outcomes (including 
scoring methods and timings of 
assessments) 
 Not stated  Agree 
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Study name 
Ring et al 
COMPLEX NON-UNION OF FRACTURES OF THE FEMORAL SHAFT TREATED BY WAVE-
PLATE OSTEOSYNTHESIS 
EAC comments 
Objective Report results of wave plate versus conventional plate techniques Agree 
Location 5 centres, USA Agree 
Design  Prospective case series Agree although the 
author mentioned their 
study as retrospective.   
Duration of study  33 months follow up Mean 33 months follow 
up (12 – 66) 
Patient population Complex ununited fractures of the femoral shaft Agree 
Sample size  42 fractures Agree 
Inclusion criteria Patients treated with a wave plate Agree 
Exclusion criteria   
Intervention(s) (n = ) and 
comparator(s) (n = )  
 Wave plate and bone graft Wave plate combined 
with bone grafting  
Baseline differences  N/A Mean age 35 yrs (13 - 
81), mean duration of 
non-union before the 
surgery was 17 months 
(6 - 68). 
How were participants followed-
up (for example, through pro-
active follow-up or passively). 
Duration of follow-up, 
participants lost to follow-up  
All patients were reviewed at regular intervals with serial radiographs and clinical 
examination. At final follow-up, the capacity to bear weight, any leg-length discrepancy, 
alignment and the range of movement in the joints of the leg were noted. 
33 months follow up, no losses to follow up 
Agree 
Statistical tests Not stated Agree 
Primary outcomes (including 
scoring methods and timings of 
assessments) 
 Radiographic and clinical healing  Agree 
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Secondary outcomes (including 
scoring methods and timings of 
assessments) 
 At final follow-up, the capacity to bear weight, any leg-length discrepancy, alignment and 
the range of movement in the joints of the leg were noted. 
Agree 
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Study name 
Wu 2003 
Reaming bone grafting to treat tibial shaft 
aseptic non-union after plating 
EAC comments 
Objective To investigate the effects of using intramedullary reaming to provide cancellous bone 
graft, and reamed intramedullary nail stabilisation to provide fragment stability on treating 
tibial shaft aseptic non-unions after plating. 
Agree 
Location Single centre, Taiwan Agree 
Design   Prospective case series Agree 
Duration of study  Follow up median 2.2 years Agree, range 1 – 5.2 
years. 
Patient population Tibial shaft aseptic non-unions 
after plating 
Agree 
Sample size 31  Agree 
Inclusion criteria Indications for this technique included a tibial shaft non-union with an inserted plate, a 
fracture level fit for traditional or locked nail stabilisation, absence of suspected infection 
and segmental bony defect at the time, and shortening of less than 2 cm. 
Agree. 
Exclusion criteria  Patients with suspicious latent deep infection were excluded from the study, Agree 
Intervention(s) (n = ) and 
comparator(s) (n = )  
 Reaming and nail insertion = 31 Agree 
Baseline differences  N/A Median age 34 (19-58). 
Median of time from 
injury to current 
treatment was 1.8 yrs 
(0.8 - 4.2) 
How were participants followed-
up (for example, through pro-
active follow-up or passively). 
Duration of follow-up, 
participants lost to follow-up  
Patients were followed up via the hospital’s Outpatients Department at 4 to 6 week 
intervals 
3 were lost to follow up 
Agree 
Statistical tests  Not stated Agree 
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Primary outcomes (including 
scoring methods and timings of 
assessments) 
 Clinical and radiographical healing processes were recorded. Bony union was clinically 
defined as the absence of pain and tenderness, and the ability of the patient to walk 
without aids. It was radiographically defined as abridgement of solid callus with cortical 
density for both segments 
Agree. Not totally 
consistent with scope.  
Secondary outcomes (including 
scoring methods and timings of 
assessments) 
 Not stated Agree 
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Appendix B.  Critical appraisal of clinical studies 
 Schofer – 2010  
Study question Response 
(yes/no/not 
clear/N/A) 
How is the question addressed in the study? Comments by the EAC 
Was randomisation carried out 
appropriately? 
 
Yes 
Treatment was assigned randomly to each subject on a 
1:1 basis in blocks of six and randomization was stratified 
within each clinical site. The randomization code was 
developed using a computer random number generator. 
Agree 
Was the concealment of treatment 
allocation adequate? 
 
Yes 
The investigators, subjects and sponsor were blinded to 
the random allocation sequence prior to initiation of 
treatment and throughout the entire duration of this 
study. 
Agree 
Were the groups similar at the outset of 
the study in terms of prognostic factors, 
for example, severity of disease?  
 
 
Yes 
Inspection of background characteristics between study 
groups showed generally good balance achieved through 
randomization 
Agr4ee 
Were the care providers, participants 
and outcome assessors blind to 
treatment allocation? If any of these 
people were not blinded, what might be 
the likely impact on the risk of bias (for 
each outcome)? 
 
 
 
 
Yes 
The investigators, subjects and sponsor were blinded to 
the random allocation sequence prior to initiation of 
treatment and throughout the entire duration of this 
study.  Once the study was complete and the last subject 
reached 16 weeks of follow-up, the randomization code 
was broken and treatment assignments revealed to the 
study statistician. Quantitative radiographic assessments 
of BMD and gap area also were undertaken without 
knowledge of treatment group assignment. 
Agree 
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Were there any unexpected imbalances 
in drop-outs between groups? If so, were 
they explained or adjusted for? 
 
 
 
No 
Seventeen subjects had missing post-treatment  
outcomes, consequently 84 subjects were included in 
descriptive analyses of ‘completers’. There was notable 
differential drop-out between groups with 24% (12 of 50) 
of sham-treated subjects and 9.8% (5 of 51) of active-
treated subjects missing post-treatment BMD values. The 
ITT cohort was preserved by imputing missing clinical 
endpoints using a multiple imputation procedure that 
minimizes bias from differential drop-outs and properly 
accounts for uncertainty in imputed values when 
performing statistical inference. 
Agree 
Is there any evidence to suggest that the 
authors measured more outcomes than 
they reported? 
 
 
No 
 Agree 
Did the analysis include an intention-to-
treat analysis? If so, was this appropriate 
and were appropriate methods used to 
account for missing data? 
 
 
Yes 
The ITT cohort was preserved by imputing missing clinical 
endpoints using a multiple imputation procedure that 
minimizes bias from differential drop-outs and properly 
accounts for uncertainty in imputed values when 
performing statistical inference. 
Agree 
 
   110 of 151 
External Assessment Centre report: EXOGEN 
Date: 22
nd
 June 2012 
 
Study name Rutten – 2008  
Study question Response 
(yes/no/not 
clear/N/A) 
How is the question addressed in the study? Comments by the EAC 
Was randomisation carried out 
appropriately? 
Yes Randomisation of treatment was computerised Agree 
Was the concealment of treatment 
allocation adequate? 
Yes Neither patient nor investigator knew whether the 
patient had received an active EXOGEN device 
Agree 
Were the groups similar at the outset of 
the study in terms of prognostic factors, 
for example, severity of disease?  
Yes Patients in both treatment groups had similar ages, 
gender distribution, fracture type and duration of 
treatment 
Agree 
Were the care providers, participants and 
outcome assessors blind to treatment 
allocation? If any of these people were 
not blinded, what might be the likely 
impact on the risk of bias (for each 
outcome)? 
Yes Unblinding of the trial was performed after completion of 
the histomorphometric and histologic analysis, and after 
all patients included in the trial completed their 5 month 
clinical treatment phase 
Agree 
Were there any unexpected imbalances in 
drop-outs between groups? If so, were 
they explained or adjusted for? 
N/A  Agree 
Is there any evidence to suggest that the 
authors measured more outcomes than 
they reported? 
No  Agree 
Did the analysis include an intention-to-
treat analysis? If so, was this appropriate 
and were appropriate methods used to 
account for missing data? 
N/A  Agree 
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Critical appraisal, randomised control trials – SURGERY 
Study name Cacchio – 2009  
Study question Response 
(yes/no/not 
clear/N/A) 
How is the question addressed in the study?  
Was randomisation carried out 
appropriately? 
Yes Randomization of the patients and monitoring of the data 
were performed in a university hospital (Department of 
Physical Medicine  and Rehabilitation, School of Medicine, 
‘‘La Sapienza’’ University, Rome) not involved in the 
treatment procedures, according to the CPMP/ ICH 
(Committee for Proprietary Medicinal 
Products/International Conference on Harmonisation of 
Technical Requirements for Registration of Pharmaceuticals 
for Human Use) Guideline for Good Clinical Practice12 and 
Guideline for Statistical Principles for Clinical Trials1 
 
Was the concealment of treatment 
allocation adequate? 
Yes IN comparison of the shockwave treatments, yes. However, 
it is impossible to conceal surgical intervention 
 
Were the groups similar at the outset 
of the study in terms of prognostic 
factors, for example, severity of 
disease?  
Yes There were no significant differences in baseline 
characteristics 
 
Were the care providers, participants 
and outcome assessors blind to 
treatment allocation? If any of these 
people were not blinded, what might 
be the likely impact on the risk of bias 
(for each outcome)? 
No The study states that it is double blind, however, only the 
independent assessors were blind to the treatment for the 
shockwave treatment group 
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Were there any unexpected 
imbalances in drop-outs between 
groups? If so, were they explained or 
adjusted for? 
Yes There was a high rate of drop out in the atrophic non-union 
group. A requirement for separate analysis was noted, but 
not carried out due to low numbers 
 
Is there any evidence to suggest that 
the authors measured more outcomes 
than they reported? 
No   
Did the analysis include an intention-
to-treat analysis? If so, was this 
appropriate and were appropriate 
methods used to account for missing 
data? 
Yes All outcome analyses were performed according to the 
intention-to-treat principle. The intention-to-treat analysis 
was carried out according to a ‘‘worst case scenario’’ 
analysis: subjects who did not complete the treatment or 
did not undergo the post-treatment or final follow-up 
assessments were assigned a poor outcome, with the final 
follow-up evaluation considered to be the last observation 
performed. 
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Study name Friedlaender 2001  
Study question Response 
(yes/no/not 
clear/N/A) 
How is the question addressed in the study? Comments by the EAC 
Was randomisation carried out 
appropriately? 
Not clear Treatment was randomly assigned, but method is not 
made clear 
Agree 
Was the concealment of treatment 
allocation adequate? 
Yes  Agree 
Were the groups similar at the outset 
of the study in terms of prognostic 
factors, for example, severity of 
disease?  
Yes These two randomly assigned populations were similar in 
most respects, including age, sex ratio, duration of non-
union, and the number of prior surgical interventions. 
There was, however, a statistically higher prevalence of 
atrophic non-unions (41 compared with 25%, p = 0.048) 
and a strong trend toward more smokers (74 compared 
with 57%, p = 0.057) in the OP-1 group. There were also 
trends toward higher percentages of comminuted 
fractures at injury, prior failures of bone autografts, and 
prior use of intramedullary rods in the individuals in the 
OP-1 treated group. 
Agree 
Were the care providers, participants 
and outcome assessors blind to 
treatment allocation? If any of these 
people were not blinded, what might 
be the likely impact on the risk of bias 
(for each outcome)? 
Not clear Surgeons were aware of treatment after randomisation, 
radiographers assessing the cases were blinded 
throughout. Low risk of bias 
Agree 
Were there any unexpected 
imbalances in drop-outs between 
groups? If so, were they explained or 
adjusted for? 
No  Agree. No loss of follow-up.  
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Is there any evidence to suggest that 
the authors measured more outcomes 
than they reported? 
No  Agree 
Did the analysis include an intention-
to-treat analysis? If so, was this 
appropriate and were appropriate 
methods used to account for missing 
data? 
No  Agree.  
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Critical appraisal, observational studies – EXOGEN 
Study name:                Gebauer  2005  
Study question Response 
yes/no/not 
clear/N/A) 
How is the question addressed in the study? Comments by the EAC 
Was the cohort recruited in an 
acceptable way? 
Yes All consecutive patients who met the inclusion criteria 
were included. The initial injury or fracture management 
was not a consideration in the study inclusion criteria. 
Agree 
Was the exposure accurately 
measured to minimise bias? 
Yes Patients followed the recommended 20 minutes per day 
until healed treatment. The EXOGEN device automatically 
provides 20 minute treatments. A patient compliance 
monitor stored the compliance data in the EXOGEN device. 
Output of daily use was downloaded when the devices 
were returned upon completion of the treatment.  
Additionally, the inclusion criterion to minimize the 
possible bias of the effects of surgery on the resulting heal 
rate was no surgical procedure during the 4 months before 
the start of EXOGEN treatment. 
Agree 
Was the outcome accurately measured 
to minimise bias? 
Yes Fracture union as determined by clinical and radiographic 
assessment. 
This is consistent with the scope. 
Have the authors identified all 
important confounding factors? 
Yes Potential variables identified as initial fracture treatment, 
subsequent surgical or other interventions during the prior 
period, demographics including gender and age, prior 
orthopaedic and surgical history including the initial injury 
type, involved bone and location within the bone, smoking 
status, non-union type, the interval in days from the last 
failed surgery to the start of EXOGEN treatment, and the 
overall fracture age. 
Agree 
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Have the authors taken account of the 
confounding factors in the design 
and/or analysis?  
Yes Data stratified by the patient and fracture characteristics.  
 
All the stratification variables were non-significant apart 
from overall fracture age, the time from the last surgical 
procedure to the start of EXOGEN treatment, bone type 
and long bones versus other bones. These were all as a 
result of failed scaphoid cases which were atrophic, each 
having a fracture age and last surgical procedure interval 
of over 10 years previously. 
Not relevant here as this is a 
case series study.  
Was the follow-up of patients 
complete? 
Yes Long term healed status of all patients was verified in a 
telephone follow up conducted approximately one year 
post study completion. Long term follow up was obtained 
for 52 of the 57 healed patients. 
Agree 
How precise (for example, in terms of 
confidence interval and p values) are 
the results?  
Yes p=0.0001 
 
Confidence interval not reported 
This is not relevant to the 
decision question as the test was 
between EXOGEN treated and 
no treatment non-union patients 
themselves. 
 
 
   117 of 151 
External Assessment Centre report: EXOGEN 
Date: 22
nd
 June 2012 
 
tudy name                   Jingushi - 2007  
Study question Response 
yes/no/not 
clear/N/A) 
How is the question addressed in the study? Comments by the EAC 
Was the cohort recruited in an 
acceptable way? 
Yes Recruitment was from a larger more inclusive study 
reported separately. Identification of cases that met these 
prospectively defined criteria was performed as defined  
Agree 
Was the exposure accurately 
measured to minimise bias? 
Yes Followed the recommended 20 minutes per day until 
healed treatment. 
Agree 
Was the outcome accurately measured 
to minimise bias? 
Yes Solid bone union as determined by X-ray evaluation plus 
usual and customary clinical healing determination 
Agree 
Have the authors identified all 
important confounding factors? 
Yes Gender, age, location of injury, Gustilo score, presence of 
operative fixation, fracture age, time since recent 
operation, number of prior surgeries, treatment time. 
Agree 
Have the authors taken account of the 
confounding factors in the design 
and/or analysis?  
Yes Full odds ratio analysis of background factors Agree 
Was the follow-up of patients 
complete? 
Yes All patients Agree 
How precise (for example, in terms of 
confidence interval and p values) are 
the results?  
N/A 75% of fractures healed plus analysis of factors 
contributing to higher or lower success rates. 
Agree 
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Study name                   Lerner  2004  
Study question Response 
yes/no/not 
clear/N/A) 
How is the question addressed in the study? Comments by the EAC 
Was the cohort recruited in an 
acceptable way? 
Yes Sought to recruit high energy fractures with delayed or 
impaired healing and did so by clinical evaluation using 
standard definitions 
Agree. 
Was the exposure accurately 
measured to minimise bias? 
Yes Followed the recommended 20 minutes per day until 
healed treatment. 
Agree. 
Was the outcome accurately measured 
to minimise bias? 
Yes Solid bone union as determined by X-ray evaluation Agree. This definition of healing 
is different from what defined in 
the scope.  
Have the authors identified all 
important confounding factors? 
Yes Age, type of injury, location of injury, cause of injury, 
Gustilo score, MESS score, presence of vascular injury, 
fixation method and flap. 
Provided description of 
characteristics of the patient 
population as a case series 
study.  
Have the authors taken account of the 
confounding factors in the design 
and/or analysis?  
Yes 16/17 fractures for which outcomes were determined 
exhibited positive outcomes, so no meaningful 
contribution from confounding factors was evidenced. 
Agree. 
Was the follow-up of patients 
complete? 
Yes For 17 out of 18 fractures Agree. 
How precise (for example, in terms of 
confidence interval and p values) are 
the results?  
N/A 16/17 fractures healed equates to 94%. Confidence interval and P value 
were not reported and 
applicable for this case series 
study.  
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Study name                         Mayr  2000  
 Response 
yes/no/not 
clear/N/A) 
How is the question addressed in the study? Comments by the EAC 
Was the cohort recruited in an 
acceptable way? 
 
Yes 
The study included all patients who met the inclusion 
criteria and who were completers 
Agree 
Was the exposure accurately 
measured to minimise bias? 
 
Yes 
The treatment method was provided for one daily 20-min 
treatment period which the patient self-administers at 
home. 
Agree 
Was the outcome accurately 
measured to minimise bias? 
 
Yes 
Healing criteria: three cortices bridged in two X-ray planes 
or trabecular bridging of at least 80%. 
Agree 
Have the authors identified all 
important confounding factors? 
Yes Age, fracture type, use of certain drugs and smoking are 
variable factors. 
Agree 
Have the authors taken account of the 
confounding factors in the design 
and/or analysis?  
Yes Results were stratified to these populations as well as 
averaged overall. 
Agree 
Was the follow-up of patients 
complete? 
Yes Only completers were measured. Agree 
How precise (for example, in terms of 
confidence interval and p values) are 
the results?  
N/A N/A Agree 
Adapted from Critical Appraisal Skills Programme (CASP): Making sense of evidence  
12 questions to help you make sense of a cohort study  
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Study name:                Nolte - 2001  Comments by 
the EAC 
Study question Response 
yes/no/not 
clear/N/A) 
How is the question addressed in the study?  
Was the cohort recruited in an 
acceptable way? 
Yes All patients who met the inclusion criteria were included  
Was the exposure accurately 
measured to minimise bias? 
Yes Patients followed the recommended 20 minutes per day 
until healed treatment. The EXOGEN device automatically 
provides 20 minute treatments. 
 
Was the outcome accurately 
measured to minimise bias? 
Yes Fracture union as determined by clinical and radiographic 
assessment. 
 
Have the authors identified all 
important confounding factors? 
Yes Potential variables identified as gender, age, fracture age, 
prior interval without surgery, bone, smoking habit, non-
union type, fixation type present before, at the start of, 
and during ultrasound treatment.  
 
Have the authors taken account of the 
confounding factors in the design 
and/or analysis?  
Yes Data stratified by the patient and fracture characteristics.  
All the stratification variables were non significant except 
for the comparison of smoking strata. 
 
Was the follow-up of patients 
complete? 
Yes All healed fractures were followed up for an average of 62 
weeks (range 30-110 weeks) 
 
How precise (for example, in terms of 
confidence interval and p values) are 
the results?  
Yes p=0.0001 
 
Confidence interval not reported 
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Study name:               Romano   1999   
Study question Response 
yes/no/not 
clear/N/A) 
How is the question addressed in the study? Comments by the EAC 
Was the cohort recruited in an 
acceptable way? 
Yes All patients who met the inclusion criteria were included Agree 
Was the exposure accurately 
measured to minimise bias? 
Yes Patients followed the recommended 20 minutes per day 
until healed treatment.  
Agree 
Was the outcome accurately 
measured to minimise bias? 
Not clear  Information not provided Yes.  
Have the authors identified all 
important confounding factors? 
Yes We did not conduct a controlled double-blind since this 
study design would not be acceptable. It denies treatment 
to one study arm and it may be impossible to carry out in 
patients suffering with infected pseudoarthrosis. In all of 
the treated cases in this study, the course of fracture 
healing showed over a period of time that there was no 
change in the healing process in the presence of an 
infection and, therefore, the patient was his own control. 
The only new event that was introduced at the start of 
treatment was the use of low intensity pulsed ultrasound. 
This is a case report study. 
Have the authors taken account of the 
confounding factors in the design 
and/or analysis?  
Yes  Not relevant. 
Was the follow-up of patients 
complete? 
Yes  Agree 
How precise (for example, in terms of 
confidence interval and p values) are 
the results?  
N/A  Agree 
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Critical appraisal, observational studies - SURGERY             
Study name                 Bellabarba 2002  
Study question Response 
yes/no/not 
clear/N/A) 
How is the question addressed in the study? Comments by the EAC 
Was the cohort recruited in an 
acceptable way? 
Yes Prospective consecutive series Agree. Case series study.  
Was the exposure accurately 
measured to minimise bias? 
Yes  Yes. Very detailed description of 
the surgery.  
Was the outcome accurately 
measured to minimise bias? 
Yes Extensive measurements in many parameters were taken 
using two scoring systems 
Yes for those which are relevant 
to the scope and other outcome 
measures.  
Have the authors identified all 
important confounding factors? 
Yes Extensive discussion of all potential confounding factors on 
p.267 
Not relevant here.  
Have the authors taken account of the 
confounding factors in the design 
and/or analysis?  
Yes Confounding factors are well measured and reported in 
the analysis 
Not relevant here.  
Was the follow-up of patients 
complete? 
Yes There was no loss to follow up Agree.  
How precise (for example, in terms of 
confidence interval and p values) are 
the results?  
N/A  Not applicable.  
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Study name                  Birjandinejad  2009  
Study question Response 
yes/no/not 
clear/N/A) 
How is the question addressed in the study? Comments by the EAC 
Was the cohort recruited in an 
acceptable way? 
Not clear Clear definition is given as to how and why patients were 
treated with this modality. Not clear whether there was 
informed consent 
Clear 
Was the exposure accurately 
measured to minimise bias? 
N/A  Yes. Had detailed description of 
the surgery process. 
Was the outcome accurately 
measured to minimise bias? 
Not clear Clear definitions of whether the fracture had healed 
radiographically and clinically. It is not clear if the assessors 
were independent 
Yes.  
Have the authors identified all 
important confounding factors? 
Not clear Infection is identified and is an exclusion factor, but little 
discussion concerns other confounding issues 
N/A 
Have the authors taken account of the 
confounding factors in the design 
and/or analysis?  
Not clear There is no discussion of this in the text N/A 
Was the follow-up of patients 
complete? 
Yes  Agree 
How precise (for example, in terms of 
confidence interval and p values) are 
the results?  
N/A  N/A 
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Study name                 Khalil  2010   
Study question Response 
yes/no/not 
clear/N/A) 
How is the question addressed in the study? Comments by the EAC 
Was the cohort recruited in an 
acceptable way? 
Yes Clear definitions of how and why patients were recruited. 
All patients gave informed consent. 
Agree 
Was the exposure accurately 
measured to minimise bias? 
N/A  Yes 
Was the outcome accurately 
measured to minimise bias? 
Yes Recognised scoring systems were used Healing rate and healing time 
were reported  
Have the authors identified all 
important confounding factors? 
Yes There is extensive discussion of potential confounding 
factors on p.441 
Not relevant to the decision 
question 
Have the authors taken account of the 
confounding factors in the design 
and/or analysis?  
Yes Clinical and radiographic outcomes were measured with 
an appropriate scoring system 
Not relevant to the decision 
question 
Was the follow-up of patients 
complete? 
Yes No loss to follow up Agree 
How precise (for example, in terms of 
confidence interval and p values) are 
the results?  
N/A  Agree 
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Study name                 Lin  2010  
Study question Response 
yes/no/not 
clear/N/A) 
How is the question addressed in the study? Comments by EAC 
Was the cohort recruited in an 
acceptable way? 
Yes Clear definition of how and why patients were recruited. 
Patients entered the study with full knowledge, treatment 
choice and consent 
Agree 
Was the exposure accurately 
measured to minimise bias? 
N/A  Yes. Two surgical processes were clearly 
described and reported.  
Was the outcome accurately 
measured to minimise bias? 
Yes Extensive measurements of primary and secondary 
outcomes 
Agree 
Have the authors identified all 
important confounding factors? 
Yes Yes, extensive discussion of all confounding factors is 
noted on p.853 
Since the comparison was between two 
surgical interventions so this did not 
address the decision question. 
Nevertheless, the baseline demographic 
characteristics provided useful 
information for the study population in 
order to facilitate comparison between 
intervention (EXOGEN) and comparator 
(surgery) in the scope.  
Have the authors taken account of 
the confounding factors in the 
design and/or analysis?  
Yes Confounding factors are clearly identified in the analysis Not relevant. 
Was the follow-up of patients 
complete? 
Yes One patient died 4 months post-op, all other patients 
completed 
Agree 
How precise (for example, in terms 
of confidence interval and p values) 
are the results?  
Yes 95% confidence interval  Agree 
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Study name                 Livani 2010 Comments by the EAC 
Study question Response 
yes/no/not 
clear/N/A) 
How is the question addressed in the study?  
Was the cohort recruited in an 
acceptable way? 
Yes Clear definition of how and why patients were recruited. 
All patients gave informed consent 
Agree 
Was the exposure accurately 
measured to minimise bias? 
N/A  Yes 
Was the outcome accurately 
measured to minimise bias? 
Not clear Clinical and radiological outcomes are clearly defined, but 
no recognised scoring system is noted 
Agree 
Have the authors identified all 
important confounding factors? 
Yes Table 1. P1026 discusses potential confounding pre-op 
factors 
Agree 
Have the authors taken account of the 
confounding factors in the design 
and/or analysis?  
Not clear Pre-op confounding factors are identified and other factors 
are identified in the results presentation 
Agree 
Was the follow-up of patients 
complete? 
Yes No loss to follow up Agree 
How precise (for example, in terms of 
confidence interval and p values) are 
the results?  
N/A  Agree 
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Study name                  Razaq 2010  
Study question Response 
yes/no/not 
clear/N/A) 
How is the question addressed in the study? Comments from the EAC 
Was the cohort recruited in an 
acceptable way? 
Yes Clear definition of how and why patients were recruited. 
All patients gave informed consent. Extensive inclusion 
and exclusion criteria noted 
Agree 
Was the exposure accurately 
measured to minimise bias? 
N/A  Yes.  
Was the outcome accurately 
measured to minimise bias? 
Yes Regular assessments were made by independent assessors Agree 
Have the authors identified all 
important confounding factors? 
Yes Data regarding patients’ age and gender and other 
characteristics like femur fracture location, type of non-
union as to whether hypertrophic or atrophic and injured 
side as to left or right, duration of fracture healing after 
exchange interlocking nailing, period of postoperative 
follow up period and complication were recorded and 
analysed using SPSS-10. 
Agree 
Have the authors taken account of the 
confounding factors in the design 
and/or analysis?  
Yes Major confounding factors detailed in tables on p.108 Not relevant 
Was the follow-up of patients 
complete? 
Yes No loss to follow up Agree 
How precise (for example, in terms of 
confidence interval and p values) are 
the results?  
N/A  Agree 
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Study name                 Ring - 1997  
Study question Response 
yes/no/not 
clear/N/A) 
How is the question addressed in the study? Comments by the EAC 
Was the cohort recruited in an 
acceptable way? 
Not clear Clear explanation of how and why patients were included. 
No details as to whether this was with informed consent 
Agree 
Was the exposure accurately 
measured to minimise bias? 
N/A  Yes, the surgical process was 
described in details.  
Was the outcome accurately 
measured to minimise bias? 
Not clear All patients were reviewed at regular intervals with serial 
radiographs and clinical examination. At final follow-up, 
the capacity to bear weight, any leg-length discrepancy, 
alignment and the range of movement in the joints of the 
leg were noted. 
Agree 
Have the authors identified all 
important confounding factors? 
Yes Age, duration of Non-union, previous operations, previous 
infection are noted  
Agree.  
Have the authors taken account of the 
confounding factors in the design 
and/or analysis?  
Yes Analysis of patients including potential confounding 
factors reported on p. 291 
Agree 
Was the follow-up of patients 
complete? 
Yes No loss to follow up Agree 
How precise (for example, in terms of 
confidence interval and p values) are 
the results?  
N/A  Agree 
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Study name                 Wu - 2003  
Study question Response 
yes/no/not 
clear/N/A) 
How is the question addressed in the study? Comments by the EAC 
Was the cohort recruited in an 
acceptable way? 
Not clear Clear description of how and why patients were included. 
No details given of informed consent 
Case reports so no informed 
consent was obtained. 
Was the exposure accurately 
measured to minimise bias? 
N/A  Yes, the process of surgical was 
described in details. 
Was the outcome accurately 
measured to minimise bias? 
Yes Clinical and radiographical healing processes were 
recorded. Bony union was clinically defined as the absence 
of pain and tenderness, and the ability of the patient to 
walk without aids. It was radiographically defined as 
abridgement of solid callus with cortical density for both 
segments.  
Agree 
Have the authors identified all 
important confounding factors? 
Yes Age, gender, initial fracture type, Initial treatment, fracture 
location,  non-union period, No. of previous operations, 
Type of 
nail used 
Agree 
Have the authors taken account of 
the confounding factors in the design 
and/or analysis?  
Not clear Reporting of patient outcomes is not shown  Not relevant.  
Was the follow-up of patients 
complete? 
No Three patients were lost to follow up Agree 
How precise (for example, in terms of 
confidence interval and p values) are 
the results?  
N/A  Agree 
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Appendix C: Results of individual studies 
Study name Schofer 2010  EAC comments 
Size of study 
groups 
Treatment  EXOGEN: n=51 Agree 
Control  Sham: n=50 Agree 
Study duration Time unit  16 weeks Agree 
Type of 
analysis 
Intention-to -
treat/per 
protocol 
The primary analysis was 
intention-to-treat (ITT) and 
involved all subjects who 
received random treatment 
assignments and initiated 
device usage. 
Agree 
 Outcome Name Increase in bone mineral 
density 
 
Agree 
Unit Hounsfield units Agree 
Effect size Value 0.53 Agree 
95% CI 0.09 to 0.97 Agree 
Statistical test 
  
Type 1-sided ANCOVA 
after multiple imputation. 
Agree 
p value  0.007 Agree 
Other outcome Name Reduction in fracture gap size Agree 
Unit mm2 Agree 
Effect size Value -0.47 Agree 
95% CI -0.91 to -0.03 Agree 
Statistical test 
  
Type Multiple imputation methods 
(1-sided) 
Agree 
p value p = 0.014 Agree 
Comments  “These findings demonstrate 
significantly greater progress 
toward bone healing after 
LIPUS treatment compared to 
no LIPUS treatment in subjects 
with established delayed 
unions of the tibia.” 
Healing rate data 
were also reported 
in the paper.  
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Study name  Rutten 2008 EAC comments 
Size of study 
groups 
Treatment  7 Agree 
Control  6 Agree 
Study duration Time unit  6 months 2 – 4 months  
Type of analysis Intention-to 
-treat/per 
protocol 
 Intention to treat Agree 
 Outcome Name  Bone volume increase Agree 
Unit  % Agree 
Effect size Value  33% greater than placebo Agree 
95% CI    
Statistical test 
  
Type  Student's independent t-test 
(two-tail). 
Agree 
p value  0.02  
Other outcome Name Mineral apposition rate Agree 
Unit µm/ day  
Effect size Value 27% greater than placebo Agree 
95% CI   
Statistical test 
  
Type Student's independent t-test 
(two-tail). 
Agree 
p value 0.04  
Comments  Although fewer than 15 
patients, In this randomised, 
double-blind, placebo 
controlled study 
histomorphometric and 
histologic analysis was 
performed to determine bone 
formation and resorption 
parameters in delayed unions of 
the osteotomized fibula. This 
the first time the influence of 
EXOGEN treatment on clinical 
fracture healing at the tissue 
level could be reported. 
Due to the small 
sample size, the fact 
that the comparator 
was not surgical 
treatment, and 
outcome measures 
were not those 
suggested in the 
scope, this study did 
not provide useful 
information to 
address the decision 
problem of interests.  
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Study name Gebauer 2005 EAC comments 
Size of 
study 
groups 
Treatment  67 fractures reported 
46 long bone fractures (tibia, femur, 
fibula, humerus, ulna, radius)  
51 long bone 
fractures.  
Control  46 51 non-union patient 
served as their own 
control  
Study 
duration 
Time unit Average healing time was 168 days. 
Patients followed up at an average 
of 402 days. 
Agree 
Type of 
analysis 
Intention-to -
treat/per protocol 
 Per Protocol and Intent to Treat Agree 
 
Outcome 
Name  Fracture Clinically and 
Radiographically Healed; time to 
healing 
Agree 
Unit  Yes / No Plus days to heal.  
Effect 
size 
Value  Per Protocol: 
 All fractures: 85% (57/67) 
healed in an average 
treatment time of 168 days 
 Long bone fractures: 89% 
(41/46) healed in an average 
time of 185 days 
Intent to Treat: 
 All fractures: 85% (70/85) 
healed 
 
 In a maximum of 
375 days follow-up, 
90% healed.  
Average healing time 
for long bone 
fractures was 178 
days.  
95% CI    
Statistical 
test 
  
Type  Fishers exact test This test is between 
EXOGEN and no 
treatment (assuming 
5% healing rate of 
non-union without 
treatment).  
p value  0.00001   
Comments Mean fracture age of the 67 
patients was 39 ± 6.2 months.  
Average number of prior failed 
surgeries = 2.0  
 Long bone non-union fractures: 
89% (41/46) (p=0.05) healed in 
an average time of 185 days 
The study did not include any 
cases that were malaligned, 
grossly instable, actively infected 
or that had extensive bone loss. 
EXOGEN produced 
90% healing rate at 1  
year for non-union.  
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Study name  Jingushi 2007 EAC comments 
Size of study 
groups 
Treatment  72 fractures Agree 
Control  N/A Agree 
Study duration Time unit  2-7 months treatment time  Not clear from the paper 
Type of analysis Intention-to 
-treat/per 
protocol 
Probably best described as PP  Agree 
 Outcome Name  Fracture healing Fracture healing rate, 
Mean fracture healing 
time 
Unit  Yes/No Days to heal 
Effect size Value  75% healed  75% for all non-union and 
delayed unions. 66% for 
non-union and 82.5% for 
delayed union. 
219days (56-588 for all 
delayed and non-union 
fractures) 
 
95% CI    
Statistical test 
  
Type  N/A Chi-squared test to 
examine relationship 
between healing rate and 
background factors, such 
as age, gender, type of 
fractures, time from the 
most recent operation to 
the EXOGEN treatment, 
number of prior surgical 
operations.  
p value    
Other outcome Name Analysis of impact of 
background factors on healing 
rate 
Agree 
Unit Odds ratio Plus Chi-squared test.  
Effect size Value There was a significant 
relationship between the 
union rate and the time from 
the most recent operation to 
the beginning of LIPUS 
treatment (P < 0.01), the time 
from the fracture to the 
beginning of treatment (P< 
0.04), and the time after the 
beginning of treatment that 
radiological improvement was 
first observed (P < 0.02) 
Agree 
95% CI   
Statistical test 
  
Type Log regression analysis Not clear what this is.  
p value See above  
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Study name  Jingushi 2007 EAC comments 
Comments  When LIPUS treatment was 
started within 6 months of the 
most recent operation, the 
union rate was approximately 
90%. In contrast, when it was 
started after 12 months, the 
union rate was less than 65% 
Agree 
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Study name  Lerner 2004 EAC comments 
Size of 
study 
groups 
Treatment  18 fractures 16 delayed long bone 
fractures 
Control  N/A Agree. 
Study 
duration 
Time unit  14 to 52 weeks treatment time 
and up to 6 years follow up 
Median 26 weeks (13 -52) 
and up to 6 years followup 
Type of 
analysis 
Intention-to -
treat/per 
protocol 
 ITT and PP ?? 
 Outcome Name  Fracture healing; time to 
healing 
Agree 
Unit  Yes/No; weeks Agree 
Effect size Value  94% healed (PP), 89% (ITT) in a 
mean of 26 weeks. 
94% healed. Mean healing 
time was 74 weeks (34 – 
224) 
95% CI    
Statistical 
test 
  
Type  Not known None 
p value    
Comments   The healing rate reported in 
text and table were not 
consistent with each other. 
Seems that the quality of the 
study and report is poor.  
 
   136 of 151 
External Assessment Centre report: EXOGEN 
Date: 22
nd
 June 2012 
 
Study name  Mayr 2000 EAC comments 
Size of study 
groups 
Treatment 42 fractures in 
prospective study  
All registry patients and local 
patients were treated by EXGEN 
Control  Prospective registry 
1317 
 
Study 
duration 
Time unit Follow up was seen up 
to 755 days 
This paper reported findings from 
patient’s registry. It is not clear how 
long those patients were followed 
up. The longest fracture was 871 
(instead of 755) days. 
Type of 
analysis 
Intention-to -
treat/per 
protocol 
ITT ?? 
 Outcome Name  Fracture healing / time 
to healing 
Agree 
Unit   % healed / days Agree 
Effect size Value See figure 5 for healing 
rates and times 
Healing rate for non-union: 69% 
(Humerus, 33/48); 95% (21/22, 
radius/ulna); 86%(57/66, femur); 
88%(105/120, tibia/tibia-fibula) 
Healing time for non-union: 174 days 
(Humerus, SD 19.5); 117 days 
(radius/ulna, SD 16.1); 157 days 
(femur, SD 10.3); 166 days 
(tibia/tibia-fibula, SD 10.6) 
Healing rate for delayed union: 76% 
(Humerus 41/54), 94%(Radius-ulna), 
87%(femur (85/98), 92%(tibia 
350/380), 96% (fibula, 26/27) 
Healing time for delayed union:  
125 days ( humerus, SD 11.7), 115 
(Radius-ulna, SD 9.3), 130 (Ulna, SD 
15.3), 140 (femur (SD 8.3), 138 (tibia 
SD 4.5), 113(fibula, 9.6). The author's 
clinic reported an average healing 
time of 130 days (SD 9.8), which is 
not significantly different with the 
registry data for delayed union of 
the tibia.  
95% CI Not known Agree 
Statistical 
test 
  
Type Not known Not clear from the paper 
p value No significant 
differences seen 
between healing times 
and rates between 
study and registry 
patient groups 
Agree 
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Study name  Mayr 2000 EAC comments 
Comments In the prospective 
study, delayed unions had 
an average fracture age of 
150 days and healed in an 
average of 129 ± 2.7 days, 
with a healing rate of 91%. 
Non-unions had an 
average fracture age of 
more than 2 years and 
healed in an average time 
of 152 ± 5.3 days with a 
healing rate of 86%. 
None of these results 
were significantly 
different to those seen 
in the prospective 
registry of 1317 patients 
The registry included other bone 
fractures so it is important to select 
relevant information within the 
scope. See above for detailed 
outcome from long bone fracture 
non-union and delayed union.  
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Study name  
 
Nolte  2001 EAC Comments  
Size of study 
groups 
Treatment 29 fractures reported 
21 long bone fractures (tibia, 
femur, fibula, humerus, ulna, 
radius)  
Essentially case series 
study.  
Control  21 Self-paired 
Study duration Time unit Average healing time was 152 
days. Patients followed up at an 
average of 62 weeks from the 
healed date (range 30-110 weeks) 
Agree 
Type of 
analysis 
Intention-to -
treat/per 
protocol 
 Per Protocol and Intent to Treat ??? 
 Outcome Name  Fracture Clinically and 
Radiologically Healed; time to 
healing 
Agree 
Unit  Yes / No ; weeks Days 
Effect size Value Per Protocol: 
 All fractures: 86% (25/29) 
healed in an average 
treatment time of 22 
weeks 
 Long bone fractures: 86% 
(18/21) healed in an 
average time of 22 weeks 
Intent to Treat: 
 All fractures: 80% (33/41) 
healed in an average 
treatment time of 20 
weeks 
 Long bone fractures: 86% 
(25/29) in an average 
treatment time of 20 
weeks 
 
Not sure where the 
sponsor ‘s outcome data 
came from. The EAC 
found the below healing 
rate within 2 years:  
100% (10/10,Tibia-
tibia/fibula), 80% (femur, 
4/5), 80% (radius-
radius/ulna, 4/5), 100 
(other long bones, 2/2).  
 
Healing time:  
144 days(Tibia-
tibia/fibula), 185(femur), 
139 (radius-radius/ulna, 
4/5), 153 (other long 
bones, 2/2) 
 
 
95% CI    
Statistical test 
  
Type  One sided  test, not specified Not very meaningful for 
the decision question.  
p value  Healed rate, significantly better 
(p< 0.0001) when compared with 
the assumed rate of 5% for the 
prior failed treatment period 
 
Other outcome Name Healing rates and times were 
stratified by  age, gender, 
concomitant disease, bone 
location, fracture age, prior last 
surgery interval, non-union type, 
smoking habits, and fixation 
before and during treatment 
Agree but beyond the 
scope. 
Unit   
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Study name  
 
Nolte  2001 EAC Comments  
Statistical test 
  
Type For stratification analyses, the 
Kruskal-Wallis test was used for 
contrasting heal time and 
fracture age and the Fisher’s 
exact test was used for healed 
rates. The Kruskal- Wallis analysis 
was a two-sided 99% confidence 
level Monte Carlo estimate of the 
exact p value computed 
Agree but beyond the 
scope. 
p value Not significant except in smokers  
Comments  Average age of the non-unions 
treated was 1.2 years, average 
number of prior surgeries = 1.4.  
Stratification of the healed and 
failed outcome for age, gender, 
concomitant disease, bone 
location, fracture age, prior last 
surgery interval, non-union type, 
smoking habits, and fixation 
before and during treatment 
showed a significant difference 
only in the smoking habit strata. 
Agree 
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Study name Romano 1999 Comments by the 
EAC 
Size of study 
groups 
Treatment 15 fractures reported 
13 long bone fractures (tibia, 
femur, humerus)  
Agree 
Control  NA Agree 
Study duration Time unit Average healing time was 152 days. 
Patients followed up at an average 
of 62 weeks from the healed date 
(range 30-110 weeks) 
Agree 
Type of 
analysis 
Intention-to -
treat/per 
protocol 
 NA Agree 
 Outcome Name  Consolidation Agree but note that 
consolidation is not 
included as 
outcome measure 
in the scope 
Unit  Consolidation, Non-consolidation, 
progression of callus but necessity 
of new surgery, still in treatment 
Agree 
Effect size Value Of the 13 long bone fractures, 8 
consolidated, 1 had progression of 
callus but required a new surgery, 
1 non-consolidation, and 3 patients 
are still in treatment  
Agree 
95% CI  NA Agree 
Statistical test 
  
Type  NA Agree 
p value  NA Agree 
Comments  “our experience demonstrates 
that this simple and non-invasive 
treatment, requiring only 20 
minutes a day of therapy at home, 
must be taken under consideration 
before performing surgical 
interventions that are both more 
complex and expensive for the 
patient and associated heath care 
organizations.” 
EAC suggests 
exclude this study 
from submission 
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Study name Friedlaender 2001 Comments by the 
EAC 
Size of study 
groups 
Treatment  61 – surgery + rhOP-1 Agree 
Control  61 - surgery 61 FOR autograft 
surgery treatment  
Study duration Time unit  24 month follow up. Primary end 
point at 9 months 
Agree 
Type of analysis Intention-to 
-treat/per 
protocol 
 Intention to treat Agree 
 Outcome Name  Healed / not healed at 9 months Agree. Healing was 
defined as bridging 
in at least three of 
four views. Fully 
weight bearing 
with less than 
severe pain was 
also used as 
outcome measure.  
Unit  Yes / No Agree 
Effect size Value  Bridging in at least three of four 
views—resulted in radiographic 
healing rates in both groups:  
62% of the OP-1 recipients and 74% 
of the autograft-treated group  
Clinical success in this study 
required a patient to be fully 
weight-bearing with less than 
severe pain at the fracture site. By 
these criteria, at 9 months 
following surgery, 81% (51 of 63) of 
the OP-1-treated group and 85% 
(52 of 61) of the autograft-treated 
group were considered to have 
successful outcomes  
Agree 
95% CI    
Statistical test 
  
Type  Chi-square test and a p value of ≤ 
0.05 was considered statistically 
different. 
Agree 
p value  p = 0.158, or radiographic healing 
p = 0.524 for clinical healing 
There was no 
statistically 
significant 
difference of  
radiographic and 
clinical healing 
outcomes between 
the two treatment 
groups. 5-10% 
patients need 
surgical re-
treatment.   
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Study name Friedlaender 2001 Comments by the 
EAC 
Other outcome Name Length of stay, operative time, and 
operative blood loss 
Furthermore, all 
patients in each 
group had at least 
one mile or 
moderate adverse 
event. 40% of 
patients in each 
treatment group 
had serious 
adverse events.  
Unit Days, hours, ml Agree 
Effect size Value The trend toward longer operative 
and hospitalization times and the 
statistically significant increased 
blood loss (p = 0.049) in the 
autograft-treated group were 
imposed by the nature of a bone 
donor recovery site. 
Agree 
95% CI   
Statistical test 
  
Type Differences in the frequency of 
adverse events were evaluated by a 
two-tailed chi-square or Fisher's 
exact test, as appropriate. 
Comparison of the means of 
operative blood loss was performed 
with a Student t test. For the length 
of stay and operative time, 
Wilcoxon rank sum tests were 
performed, which are appropriate 
for variables that are not normally 
distributed. A p value of ≤ 0.05 for 
analysis of safety variable was 
considered significant. 
Agree 
p value See effect size  
Comments   Both treatments 
are surgical 
intervention. 
Similar outcomes 
and high chance of 
adverse events 
were observed.  
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Study name  Bellabarba 2002 Comments by the 
EAC 
Size of study 
groups 
Treatment  20 Agree 
Control  N/A Agree 
Study duration Time unit  Maximum follow up 60 months, 
average 23 
Agree 
Type of 
analysis 
Intention-to -
treat/per 
protocol 
 ITT ? 
 Outcome Name  Healed / not healed Agree 
Unit  Radiographic healing + full weight 
bearing 
Agree 
Effect size Value  100% union at an average of 14 
weeks 
Agree 
95% CI  N/A Agree 
Statistical test 
  
Type  N/A Agree 
p value  N/A Agree 
Other outcome Name Böstman and HSS scores for post-
operative assessment 
Agree but this 
outcome is beyond 
the scope 
Unit Good to excellent results in 19 
patients 
See above 
Effect size Value Not known  
95% CI N/A  
Statistical test 
  
Type Not known  
p value N/A  
Comments    
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Study name  Birjandinejad 2009 EAC Comments 
Size of study 
groups 
Treatment  25 femoral non-unions , 13 tibial 
non-unions 
Agree 
Control  N/A Agree 
Study duration Time unit  1 year follow up Agree 
Type of 
analysis 
Intention-to -
treat/per 
protocol 
 ITT ?? 
 Outcome Name  Healed / not healed Agree 
Unit  Radiographic + clinical 
observation 
Agree 
Effect size Value  100% femur healed,  Tibia 84.6 
healed – average time to union 
was 4.78 months 
Agree 
95% CI  N/A Agree 
Statistical test 
  
Type  Not known Agree 
p value  N/A Agree 
Comments  No non-unions were infected Non-union was not 
clearly defined in 
the paper. 
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Study name  Lin 2010 EAC Comments 
Size of study 
groups 
Treatment  Autograft – 28 Agree but both 
treatment and control 
were surgery.  
Control  Allograft - 37 Agree 
Study duration Time unit  2 years Agree 
Type of 
analysis 
Intention-to -
treat/per 
protocol 
 ITT ?? 
 Outcome Name  Healed / not healed; time to 
healing 
Agree 
Unit  Yes / No; weeks Agree 
Effect size Value  95% v 93%; 18.8 v 20.1 
weeks 
Agree 
95% CI  (-0.1 to 0.14) ; (-3..7 to 0.77) Agree 
Statistical test 
  
Type  Continuous variables – 
student’s t test, binary 
variables chi squared or 
Fisher’s exact 
Agree 
p value  0.85 ; 0.22 Agree 
Other outcome Name Post-op Neer score ; Post-op 
DASH score 
Agree 
Unit   
Effect size Value 90.8±6.6 v 88.5 ±6.9 ; 20.5 
±5.2 v 17.6 ± 7.5 
Agree 
95% CI (-1.11 to 5.71) ; (-0.62 to 
6.02) 
Agree 
Statistical test 
  
Type Continuous variables – 
student’s t test, binary 
variables chi squared or 
Fisher’s exact 
Agree 
p value 6.18 ; 0.11 Agree 
Comments  At patients request 11 in the 
autograft and 16 in the 
allograft had their nail 
removed, involving a further 
surgical procedure. 
Agree 
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Study name  Livani 2010 EAC Comments 
Size of study 
groups 
Treatment  15 Agree 
Control  N/A Agree 
Study duration Time unit  Average follow up 35.8 months Agree 
Type of 
analysis 
Intention-to -
treat/per 
protocol 
 ITT ??? 
 Outcome Name  Healed / not healed; time to 
healing 
Agree 
Unit  Yes / no; weeks Agree 
Effect size Value  100% healed -  average time to 
healing was nine weeks 
Agree 
95% CI  N/A Agree 
Statistical test 
  
Type  Not known N/A 
p value  N/A Agree 
Comments    
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Study name  Razaq 2010 EAC Comments 
Size of study 
groups 
Treatment  43 fractures in 41 patients Agree 
Control  N/A Agree 
Study duration Time unit  Follow up maximum 18 months Agree 
Type of 
analysis 
Intention-to -
treat/per 
protocol 
 ITT ???? 
 Outcome Name  Healed / not healed; time to 
healing 
Agree 
Unit  Yes / no  
Effect size Value  90% healed – 4.97± 1.53 months Agree 
95% CI  N/A  
Statistical test 
  
Type  Not known Agree 
p value  N/A  
Comments  No infected fractures were treated 
in this study 
Adverse events were 
reported.  
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Study name  Ring 1997 EAC Comments 
Size of study 
groups 
Treatment  42 Agree 
Control  N/A Agree 
Study duration Time unit  Maximum follow-up 66 months, 
mean 33  
Agree 
Type of 
analysis 
Intention-to -
treat/per 
protocol 
 ITT ??? 
 Outcome Name  Healed / not healed – time to 
healing 
Union was judged 
clinically by the absence 
of pain on weight 
bearing and on 
radiographs by evidence 
of incorporation of bone 
graft at the site of non-
union and cortical 
changes.  
Unit  Yes / no – months Agree 
Effect size Value  97% healed – average time to 
healing = 6 months. However, 
three of these patients required 
secondary  surgical intervention 
Agree 
95% CI  N/A Agree 
Statistical test 
  
Type  Not known N/A 
p value  N/A N/A 
Other outcome Name Range of movement Agree 
Unit   
Effect size Value All patients had full mobility at the 
hip and ankle, and 31 (72%) 
regained full movement at the 
knee. Seven had residual 
limitation of knee flexion and two 
lacked 10° of extension. One 
patient with severe limitation of 
knee flexion required quadriceps 
lengthening, which gave a range 
of 1° to 60° at the latest follow-up. 
One patient had residual knee 
instability. 
Agree but this is not the 
outcome measure 
relevant to the scope 
95% CI N/A Agree 
Statistical test 
  
Type Not known Agree 
p value N/A Agree 
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Study name  Ring 1997 EAC Comments 
Comments Patients with previous infection 
were treated. Two patients with 
previous infection had recurrence. 
One of the fractures failed to 
unite; the other healed, but 
developed a draining fistula. 
Another patient with persistent 
non-union had a second bone-
grafting procedure 12 months 
after the insertion of a wave plate 
and the fracture had united by 18 
months. Two of the four patients 
in whom a large bony defect had 
been treated with a vascularised 
fibular graft required an additional 
grafting procedure before union. 
These were process 
related adverse events, 
which are relevant to 
the scope. 
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Study name  Wu 2003 EAC Comments 
Size of study 
groups 
Treatment  31 – 28 were followed up  Agree 
Control  N/A Agree 
Study duration Time unit  Mean follow up 2.2 years 
,maximum 5.2 years 
Median 2.2 years 
Type of analysis Intention-to -
treat/per 
protocol 
 Per protocol as the losses to 
follow up were discounted 
??? 
 Outcome Name  Healed / not healed ; time to 
healing 
Agree 
Unit  Yes / no / months Agree 
Effect size Value  100% union,(excluding 3 losses to 
follow up) mean 4.5 months 
(range 3 – 7.5) 
All fractures healed 
eventually but it was 
not clear when was 
the cut-off assessment 
point.  
95% CI  N/A Agree 
Statistical test 
  
Type  Not known Agree 
p value  N/A Agree 
Comments No infected fractures were 
included 
Agree 
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